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Résumé 
L'arthrose est une maladie multifactorielle complexe. Parmi les facteurs impliqués dans sa 
pathogénie, les certains prostaglandines exercent un rôle inflammatoire et d’autres un rôle 
protecteur. La prostaglandine D2 (PGD2) est bien connue comme une PG anti-inflammatoire, 
qui est régulée par l’enzyme «Lipocalin prostaglandine D-synthase». Avec l’inflammation de 
l'arthrose, les chondrocytes essaient de protéger le cartilage en activant certaines voies de 
récupération dont l'induction du gène L-PGDS. Dans cette étude, nous étudions la voie de 
signalisation impliquée dans la régulation de l'expression du (L-PGDS) sur les chondrocytes 
traités avec différents médiateurs inflammatoires. 
Le but de projet: Nous souhaitons étudier la régulation de la L-PGDS dans le but de 
concevoir des approches thérapeutiques qui peuvent activer la voie intrinsèque anti-
inflammatoire. 
Méthode et conclusions: In vivo, l'arthrose a été suivie en fonction de l’âge chez la souris 
ou chirurgicalement suivant une intervention au niveau des genoux de souris. Nous avons 
confirmé les niveaux d’expression de L-PGDS histologiquement et par immunohistochimie. In 
vitro, dans les chondrocytes humains qui ont été traités avec différents médiateurs de 
l'inflammation, nous avons observé une augmentation de l’expression de la L-PGDS dose et 
temps dépendante. Nous avons montré,  in vivo et in vitro que l’inflammation induit une 
sécrétion chondrocytaire de la L-PGDS dans le milieu extracellulaire. Enfin, nous avons 
observé la production de différentes isoformes de la L-PGDS en réponse à l'inflammation.  
Mots clés: l'arthrose, Lipocalin prostaglandine synthase D, l'interleukine 1 bêta, la 
prostaglandine D2. 
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Abstract 
Osteoarthritis is a complex multifactorial disease; many factors are involved in its 
pathogenesis, among those factors prostaglandins. Some prostaglandins have inflammatory 
role and some have anti-inflammatory role. Prostaglandin D2 (PGD2) is a well-established 
anti-inflammatory PG which is synthesized by the Lipocalin prostaglandin-D synthase (L-
PGDS) enzyme. Upon the initiation of the inflammatory process in osteoarthritis, 
chondrocytes try to save themselves by activating salvage pathways, among these pathways 
is the induction of L-PGDS gene. In this study we are addressing the signaling pathways 
involved in the regulation of (L-PGDS) gene expression, in chondrocytes treated with different 
inflammatory mediator.  
Rationale: understanding the regulation of L-PGDS will allow us to design therapeutic targets 
that can switch on the intrinsic anti-inflammatory pathway.  
Method and findings: In vivo, osteoarthritis was induced in mice knees surgically or naturally 
following aging, the development of osteoarthritis was then confirmed histologically. The 
expression levels of L-PGDS were detected by Immunohistochemistry. In vitro, human 
chondrocytes were treated with different inflammatory mediators (interleukin-1 beta, 
interleukin-17, hydrogen peroxide and tert-Butyl hydroperoxide). Interestingly, in most cases 
chondrocytes increased expression of L-PGDS in a dose and time dependent manner. We 
discovered that chondrocytes release L-PGDS into the extracellular space in response to 
inflammation, in vivo and in vitro. Lastly we observed different isoforms of L-PGDS generated 
in response to inflammation. 
Key words: osteoarthritis, Lipocalin prostaglandin D synthase, interleukin 1 beta, 
prostaglandin D2. 
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A. Introduction 
1.1 Osteoarthritis:  
Osteoarthritis (OA) is a chronic inflammatory degenerative disease that affects joints 
cartilage, ligaments and underlying bone. It was long thought to be an inevitable 
process of aging. Further studies on OA revealed the interplay between many 
pathophysiological factors namely: weight, age, sex, genes, biomechanical, 
biochemical, environmental and local factors in the joint itself.  In normal joints, there 
is a balance between the anabolic and the catabolic processes, at the level of 
articular cartilage, bones and synovial membranes. In OA, this balance is disrupted 
leading to the classic features of OA like degradation of articular cartilage (leading to 
narrowing of joint space), subchondral bone remodeling (osteosclerosis) and cyst 
formation, osteophytes formation and synovial membrane inflammation and 
thickening.  Normal anatomy of the knee joint is detailed in Figure 1. Figure 2 is a 
diagram showing the pathological changes in osteoarthritic knees versus normal 
knees.  
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Figure 1: Normal anatomy and structure of knee joint. 
Image source: http://commons.wikimedia.org/wiki/File:Knee_diagram.svg (open use). 
 
Figure 2: Diagram of normal Knee versus osteoarthritic one showing pathological 
features of OA. 
Image source: http://www.maurascollege.org/images/cervical-spondylosis-dizziness-treatment-information-
disease-colorado-westminster-8933.jpg   
4 
 
 
1.2 Epidemiology and risk factors:  
OA is the most common joint disease in North America, with an incidence of 10% in 
males and 15% in females above age 60. It’s expected that the total number of OA 
cases is going to grow with the aging of the population. There are many factors that 
affect the epidemiological distribution of OA cases, among these factors; the definition 
of what OA truly is, the method used to characterize it, the joints involved and the risk 
factors. For example, if we are going to check the prevalence among developed 
countries we may find obesity as a confounding factor raising the prevalence in this 
population. If we measure it among different age groups, the older the age group from 
which we take our samples the more prevalent the disease becomes. Most clinicians 
characterize OA radiologically according to the Kellgren and Lawrence scaling system 
where:  
• Grade 0: no radiographic features of OA are present. 
• Grade 1: doubtful joint space narrowing (JSN) and possible osteophytic lipping. 
• Grade 2: definite osteophytes and possible JSN on the anteroposterior weight-
bearing radiograph. 
• Grade 3: multiple osteophytes, definite JSN, sclerosis, possible bone 
deformity. 
• Grade 4: large osteophytes, marked JSN, severe sclerosis and definite bone 
deformity. 
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Regarding those patients radiologically characterized as OA, let us take the knee joint 
in people ≥ 40 years old as an example. In this population, the prevalence of knee OA 
was 19.2% according to the Framingham Study and 27.8% according to the Johnston 
County OA Project [1]. In the third National Health and Nutrition Examination Survey 
(NHANES III) researchers took a group of people >60 years old and characterized 
radiologically OA in their knees. They found that 37% of the study population had OA 
[1]. This suggests that different age groups have different prevalence. Conversely, if 
we take another factor such as which joint is involved, and we focus on hand OA for 
example, we will find the prevalence is 27.2% of the study subjects in the 
Framingham study. In addition, hip OA is less prevalent than knee OA or hand OA, 
with about 7% of women aged ≥65 years having a radiologically diagnosed OA. In 
Johnston County, the prevalence rate of hip OA reached 27% for individuals >45 
years old [1]. Hence, in different age groups, the prevalence is totally different, as 
assessed by the Framingham study of hand OA (6.8%) and knee OA (4.9%) of the 
study subjects aged ≥26 year which is much different from the other study groups. 
These differences in data reflect how different factors can affect the prevalence of 
OA, among those factors the definition of OA and the basis used to diagnose it i.e. 
clinically or radiologically, which joint is considered, and which age group is 
considered in the studies provided. OA is multifactorial in origin and factors such as 
age, gender, joint injury, body weight, bone density, collagen diseases (Ehlers-Danlos 
syndrome, Marfan syndrome) and muscle weakness around the joints are all 
important factors contributing to OA. Their modification determines the course of the 
disease. Genetic factors play a role also in the OA process [2, 3]. In a study to identify 
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the genetic loci that were associated with radiologically evident OA, researchers 
identified loci in 296 pedigrees on chromosomes 1, 7, 9, 13, and 19 particularly for 
OA of the hand [4]. OA of the hip also showed some genetic linkage to chromosome 
11 [5]. Other chromosomes are also involved including 4 and 16 [6], 2 and 19 [7]. 
Chromosomes 2, 3 and 4 were shown to be involved in mutations in matrilin-3, a 
gene for non-collagenous matrix protein (MATN3). This mutation is found in 2% of 
hand OA patients in Iceland [8]. For patients with radiologically diagnosed OA of the 
knee single-nucleotide polymorphisms (SNPs) marker association within the gene for 
Leucine-Rich Repeats and Calponin Homology (LRCH1) on chromosome 13 was 
shown in studies from the UK and Canada [9]. In addition, the marker (rs91242a C/T) 
allele was detected more frequently in cases with significant knee OA versus control 
cases. Indeed, one out of 31 identified loci shows up more frequently in OA versus 
controls [9]. The function of the protein product of this gene is not fully known though 
it has a region similar to that of actin-binding protein that plays a role in cell shaping 
and intracellular signaling. Mutations which happen in structural components of 
articular cartilage and bone tissue potentiate the effect of other risk factors of OA and 
accelerate the pathology of the disease [3].     
In conclusion the epidemiology and risk factors of OA are affected by the way you 
identify the cases, clinically versus radiologically, which joints are included, and which 
age group is targeted.   
Age, race, acute and chronic repetitive trauma, are the main risk factors for OA, 
especially in the knee joint. To a lesser extent, they affect hip and hand OA. Age, 
obesity and gender, on the other hand, have a big role in the development of hip OA.  
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Bone mass in women, and whether they use hormonal replacement therapy or not, 
also play a role in the development of hip OA. Interestingly the higher the bone mass 
before and after menopause the higher the risk of developing OA of hip joints [10, 11].  
Finally, obesity is the strongest modifiable risk factor for OA. Its strongest association 
is with the knee and hand OA while interestingly it’s less associated with hip OA [12, 
13]. Given this association, a reduction in weight has a noticeable protective role 
against knee OA [14].   
1.3 Pathogenesis:  
OA is a complex multifactorial disease and the mechanisms involved in its 
pathogenesis are not fully uncovered yet. There are different mechanisms that could 
initiate OA [15]. The most common initiating factor for OA is the mechanical damage, 
either as a single event macro-trauma or repeated microtraumas [16]. These 
mechanical injuries initiate the inflammatory process in chondrocytes causing them to 
release degenerative enzymes that degrade articular cartilage [16]. Another less 
common mechanism is the defective collagen type 1 and 2 formations in certain 
diseases leading to articular cartilage failure under normal mechanical loads [17]. 
Once the initial factor (for example trauma) starts the OA process, many other factors 
get involved. These factors include (on the molecular level) proteases, proteases 
inhibitors and cytokines, affecting the cartilage degeneration and repair balance. On 
the non-molecular level, other factors also play a role like age, weight, joint alignment, 
physical activity, and systemic hormones and mineral deposition. The biochemical 
cell response to mechanical stressors is termed mechanotransduction [18]. This 
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process has been studied in different cell types including chondrocytes [19]. Studies 
showed an increase in aggrecan messenger ribonucleic acid (mRNA) and a decrease 
metalloproteinase 3 mRNA by quantitative polymerase chain reaction (qPCR) in 
healthy human chondrocytes when cultures were subjected to repetitive loading 
versus those grown on solid support [20]. Osteoarthritic cartilages respond differently 
from healthy ones to the same mechanical loads, as they show more deformability 
and more loss of fluids under the same load [21]. These different biomechanical 
responses make normal every day loads considered pathological for osteoarthritic 
cartilage [22]. Biomechanical signaling pathways become now therapeutic targets to 
ameliorate the response of osteoarthritic cartilage to mechanical load. The difference 
in response between normal chondrocytes and osteoarthritic chondrocytes to the 
same mechanical load is what lead to the use of autologous chondrocytes 
implantation in OA. This therapeutic technique is aiming to improve the inflammatory 
process by restoring the normal signaling pathway by using healthy chondrocytes 
[23].    
Trauma, even blunt ones make the cartilage susceptible to OA and degeneration. 
Tumor necrosis factor alpha (TNF-α) levels were observed to be high in synovial fluid 
early after trauma. TNF-α enhances neutrophils mediated proteoglycans degradation 
and has pro-apoptotic effect under certain enabling conditions [24]. Interestingly 
exposing chondrocytes in vitro to TNF-α did not increase cell death rates or levels of 
prostaglandin E2 (PGE2) or prostaglandin D2 (PGD2). Trauma, on the other hand, 
increased these mediators, independently of TNF-α [24]. TNF-α was found to induce 
the expression of matrix metalloproteinase-1 (MMP-1) regardless of trauma, 
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contributing to cartilage degradation. These mediators clarify to some extent the 
biomechanical pathways involving trauma and cartilage damage.  
The role played by mechanical load is not fully understood in the pathogenesis of OA. 
It was thought to cause wear and tear to the cartilage, accelerating OA. Further 
clinical and research data revealed that mechanical load in the form of exercise (in 
normal weight subjects) can cause, accelerate, ameliorate and even reduce the risk 
of OA [25, 26].  In 2013, a systematic review of clinical trials on the effect of exercise 
on osteoarthritic weight-bearing joints (knee mainly) was done [27]. This review 
included 60 clinical trials with 12 different exercise intervention programs [27]. The 
review concluded to a statistically significant effect for exercise in reducing pain and 
improving functionality in osteoarthritic patients, particularly aquatic exercise [27]. 
Fewer similar studies were done for hip joint OA, where it was shown that 
physiotherapy and home-based exercise programs don’t provide that much 
improvement in pain management and functionality [28]. Another study evaluated the 
effect of an intensive aerobic exercise program in patients with moderate to severe 
OA evidenced clinically and radiologically (grade III and IV). This study concluded 
that, there is no difference between exercise groups versus non-exercise groups 
regarding pain control and functionality [29]. In conclusion, exercise programs have to 
be tailored depending on many factors in each patient. We should always take into 
consideration the general medical condition of the patient particularly his 
cardiovascular capacity for exercise and whether his main complaint from OA is pain 
or limitation of movement. On the other hand, limitation of movement had put the 
osteoarthritic patients who are not following an exercise program at a higher risk for 
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cardiovascular diseases. This raises the question of screening sedentary 
osteoarthritic patient for cardiovascular diseases before assigning them to exercise 
programs. Excessive mechanical load induces biomechanical transformations in 
chondrocytes, for example cyclooxygenase 2 (COX-2) gene induction. These 
biomechanical transformations impair chondrocytes’ ability to handle oxidative stress, 
which leads to chondrocyte toxicity and eventually OA [30]. This mechanical load on 
chondrocytes was also found to induce the lipocalin prostaglandin D synthase (L-
PGDS) gene. L-PGDS through its end products PGD2 and 15d-PGJ2 is hypothesized 
to contribute to the different processes initiated by mechanical load [30]. Figure 22 
clarifies the biosynthesis of PGD2 and 15d-PGJ2. 
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1.4 Treatment:  
 
Pharmacological and non-pharmacological management of OA mainly targets pain 
control, minimizing disability and improving the quality of life. General non-
pharmacological management focuses on weight reduction and exercise programs.  
Pharmacotherapy starts with acetaminophen for OA patients not showing 
inflammatory signs and symptoms [31]. Once there are symptoms of inflammation 
such as articular swelling, morning stiffness, night pain, joint effusion by examination, 
or synovitis on arthroscopic examination, non-steroidal anti-inflammatory drugs 
(NSAIDs) are indicated.  
NSAIDs can be non-selective cyclooxygenase (COX) inhibitors including COX-1 and 
COX-2, or COX-2 selective inhibitors (coxib). NSAIDs should be started at the 
minimal dose that controls the inflammation to avoid the side effects of these drugs. 
NSAIDs and Capsaicin (topical analgesic) can be used topically in patients who can’t 
tolerate NSAIDs orally. Patients with gastritis, peptic ulcer or renal diseases are 
intolerant to NSAIDs.  
Intra-articular glucocorticoids injection is the next step when there is an inadequate 
response to non-pharmacological management plus acetaminophen or NSAIDs. 
Failure of the initial therapeutic lines necessitates a re-evaluation of the joint to detect 
the probability of another underlying pathology such as crystal disease and other 
inflammatory arthropathies. This could be done by arthrocentesis and synovial fluid 
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examination. Current data suggests an added value for the use of glucosamine and 
chondroitin together versus the use of each of them alone in treating OA.  
Resistant cases of OA are treated by another spectrum of medications designated for 
those cases particularly. Those medications include opioid analgesics, intra-articular 
hyaluronans, a trial of glucosamine or chondroitin, and finally colchicine. These 
management guidelines are in accordance with the guidelines from American College 
of Rheumatology [31].  
American college of rheumatology (ACR) stated guidelines for managing OA 
according to joints involved and according to modality of treatment as follow [36]: 
Non-pharmacologic management of hand OA: 
1) Determine how OA affects the patient’s activities of daily living (ADLs). 
2) Educate the patient about how to protect his joints.  
3) Use supporting devices, like splints for patients with trapeziometacarpal OA. 
4) Educate the patient about thermal techniques available for his condition.  
Pharmacologic management of hand OA: 
1) Topical capsaicin. 
2) Topical NSAIDs. 
3) Oral NSAIDs. 
4) Tramadol. 
13 
 
 
ACR recommends against the use of intra-articular therapies and opioid analgesics. 
Generally persons who are ≥75 years old should use topical anti-inflammatory rather 
than oral ones. 
Non-pharmacologic management of knee OA: 
1) Aerobic exercise. 
2) Aquatic exercise. 
3) Weight loss.  
4) Self-management training.  
5) Physiotherapy plus exercise.  
6) Psychosocial guidance and support.  
7) Knee protective gears according to the internal lesion, for example medially 
directed patellar taping, and medially wedged insoles for those who have OA in lateral 
knee compartment or laterally wedged subtalar strapped insoles for medial knee 
compartment OA patients.  
8) Advised about thermal and transcutaneous electrical stimulation modalities 
available.  
9) Use supporting devices like walking aids as needed.  
10)  Tai chi programs. 
11)  Chinese acupuncture. 
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ACR didn’t provide specific recommendations regarding balance exercises, 
strengthening exercises, laterally wedged insoles, physiotherapy alone, knee braces 
or laterally directed patellar taping. 
Pharmacologic management of knee OA: 
1) Acetaminophen. 
2) Oral NSAIDs. 
3) Topical NSAIDs. 
4) Tramadol. 
5) Intra-articular corticosteroid injections. 
6) Chondroitin sulfate. 
7) Glucosamine. 
8) Topical capsaicin. 
Also, ACR didn’t have specific recommendations regarding the use of intra-articular 
hyaluronates, duloxetine, and opioid analgesics. 
Non-pharmacologic management of hip OA: 
1) Aerobic exercise. 
2) Aquatic exercise. 
3) Weight loss.  
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4) Self-management training.  
5) Physiotherapy plus exercise. 
6) Psychosocial guidance and support.  
7) Advised about thermal modalities and walking aids, as needed.  
ACR didn’t have particular recommendations regarding balance exercises alone or 
with strengthening exercises, tai chi or physiotherapy alone.  
Pharmacologic management of hip OA: 
1) Acetaminophen. 
2) Oral NSAIDs. 
3) Tramadol. 
4) Intra-articular corticosteroid injections. 
ACR does not recommend the use of Chondroitin sulfate and Glucosamine and didn’t 
have specific recommendations for topical NSAIDs, Intra-articular hyaluronate 
injections, Duloxetine or opioid analgesics. 
Many studies had evaluated the role of NSAIDs in OA and the mechanisms by which 
they work. The initial idea was that NSAIDs work only by inhibiting COX enzymes, but 
recently it was discovered that they downregulate the expression of the COX gene as 
well [32]. Figure 3 explains the synthesis of different PG’s from AA by COX enzyme. 
NSAIDs affect the synthesis of all prostaglandins (PG’s), the inflammatory as well as 
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the anti-inflammatory ones. This explains NSAIDs limited success in reversing or 
even stopping the progression of the disease. The moment we stop COX2 by NSAIDs 
we stop both the inflammatory and the salvation pathways. COX 1 and 2 activities are 
augmented by interleukin 1 beta (IL-1β) and arachidonic acid (AA) to produce 
different types of PG’s, as explained in Figure 3. The L-PGDS enzyme synthesizes 
PGD2 which contributes to the anti-inflammatory pathway through its end product 15-
PGJ2. Via its inhibition of nitric oxide (NO) production PGD2 prevents cartilage 
degradation [33]. PGD2 even has a positive feedback effect on its own production 
through the stimulation of COX2; this is believed to be through its role in up-regulating 
other prostanoids such as PGF1α, PGF2α and thromboxane B2 (TXB2). PGE2 
induces MMP1 and MMP13 which are inflammatory mediators in OA, and it inhibits 
proteoglycans promoting matrix degradation. PGD2, on the other hand, inhibits 
MMP1 & MMP13; this again suggests an anti-inflammatory role for PGD2. NSAIDs by 
blocking COX function and down-regulating it alter these entangled reactions, 
stopping the inflammatory and anti-inflammatory pathways. Figure 3 explains the 
synthesis of different PG’s from AA by COX enzyme.  
Guidelines recommend the use of intra-articular glucocorticoids in cases of moderate 
to severe pain, especially after the failure of oral and topical management, or when 
they are contraindicated, like in cases of active peptic ulcer disease or renal failure 
[34-37]. This effect reaches its peak during the 1st two weeks after injection and then 
it wanes off. Even with the repeated injections, their efficacy is appreciated during the 
first year only [38]. No long-term benefits or harms had been proven for this modality 
of treatment [35]. The injected dose depends on the joint size, from 10mg for small, 
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20mg for medium sized and 40mg for large ones. All injection techniques should be 
done under complete aseptic conditions to minimize the risks of infection. Guidelines 
also recommend aspiration of any joint effusion before injection of steroids and 
sending the effusion fluid for analysis for better diagnosis and to exclude infection. 
Injection of steroids should be postponed until the culture results come back negative, 
especially if there is a high suspicion for infection like fever or rapidly accumulating 
joint effusion [39].  
Studying the efficacy of this therapeutic modality showed a significant effect for intra-
articular glucocorticoids injection versus placebo [34], even without a clinically evident 
joint inflammation [35]. Most studies were done on knee joint injections, then on the 
hip joint, and to a much lesser extent on carpometacarpal joints and other joints. 
Generally these injections cause pain relief rather than improvement of function or 
repair of joint damage.  
Guidelines recommend the use of intra-articular hyaluronan injections in cases of OA 
(especially knee OA) which failed oral and topical therapeutic modalities, or in those 
patients who have a contraindication for the use of NSAIDs like active gastric ulcer or 
renal failure [31, 37]. Also, it’s the next step in cases of failure of intra-articular 
glucocorticoids injection [34-37]. This modality improves mainly pain symptoms and to 
some extent functionality but doesn’t prevent the progress of the disease or reverse it 
[40, 41]. Improvement of functionality in hyaluronan use is mainly through restoring 
the viscoelasticity of the synovial fluid that is usually lost in OA. These benefits were 
elaborated by many randomized trials and meta-analyses [42-46]. These injections 
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are usually given as one course per year (as one injection or five weekly injections 
according to the molecular weight (MW) of the drug). This is usually well tolerated at 
this rate with minimal to no side effects. Compared to glucocorticoids injections the 
hyaluronan compounds have similar efficacy with a slower onset of action, taking 
sometimes up to two months to reach its peak effect [47]. Studies compared also the 
effect of hyaluronan injections to that of NSAIDs and found almost similar effects [34, 
42, 48, 49]. Hyaluronan showed some adverse reactions like flaring of the joint pain 
and swelling post injection in 1.5 to 5 percent of patients. These flares usually 
resemble septic arthritis with synovial fluid leukocytosis of 100,000 per mm3 [50]. 
These flares are related to injection techniques as well as to the MW of the injected 
drug, with higher rates in lateral approach versus medial one [51]. Also, higher rates 
of flares were found with the use of higher MW compounds compared to lower MW 
ones [52]. Generally no major side effects for these compounds were reported. 
Surgical management is usually left as the last resort treatment of OA. There is a 
wide range of modalities available with different selection criteria for each modality. 
Arthroscopic intervention: it starts with joint irrigation [53] to improve visualization of 
the joint by removal of debris and blood. Following this, arthroscopy is used for 
debridement with or without arthroscopic synovectomy. Some hypotheses suggest 
that joint irrigation alone has a beneficial effect on the management of joint pain, by 
removal of tissue debris, crystalline materials and cartilage fragments, decreasing the 
burden on the joint and synovial membranes and slowing further destruction [54, 55]. 
Arthroscopic irrigation and lavage are an office procedure that can be done under 
local anesthesia and intravenous sedation.  
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Arthroscopic debridement is done mainly for meniscal tear usually with joint lavage. 
Some studies suggested that there is not much difference between arthroscopic 
debridement with lavage in addition to medical and physical therapy, compared to 
medical and physical therapy alone. This is regarding the pain level using WOMAC 
pain score [56]. Some randomized trials on patients with knee OA and meniscal tears 
showed no higher benefit with arthroscopic surgery, followed by physical therapy, 
compared to physical therapy alone [57-59].  
Arthroscopic abrasion includes mainly drilling of sclerotic bone in affected joints. 
Randomized controlled trials did not show significant improvement with this technique 
compared to medical and physical therapy alone. Follow-up observations of patients 
who went through this procedure showed that 50 percent still needed a total knee 
replacement within 3 years [60].  
No clinical trials were done to study the efficacy of arthroscopic synovectomy in 
patients with OA. This is usually reserved to those with severe inflammatory signs 
and symptoms unresponsive to initial NSAIDs, intra-articular glucocorticoid injections, 
arthroscopic irrigation, colchicine, and non-pharmacological measures.   
Total joint replacement (arthroplasty) is another modality used as a final measure 
after the failure of other measures and in patients with significant limitation of 
activities [61]. Replacement surgery should be timed perfectly, ideally before 
significant joint deformity or instability, significant contractures or muscle atrophy. This 
aims to minimize the complications and to maximize outcomes [62, 63]. Preoperative 
medical management and postoperative rehabilitation affect greatly the surgical 
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outcomes [64, 65]. Total joint arthroplasty usually provides the best pain relief and 
functional improvement in patients with significant hip or knee OA [61, 66]. 
Improvement of functionality following surgery comes gradually, usually over a period 
of one year and lasts in average 5 years [67].  
The joint resurfacing procedure is a treatment modality in which a metal cab or 
prosthesis replaces an arthritic femoral head; on the other side of the joint a metal 
acetabular component forms the articulation surface with the metal femoral head. 
This is known also as resurfacing arthroplasty, a common alternative for total hip 
replacement. This procedure shows some late complications, mainly femoral neck 
fracture and aseptic loosening. Other than these complications, this procedure is 
usually well tolerated and has excellent outcomes [68].  
The chondrocyte grafting technique involves autologous chondrocytes implantation 
(ACI) into the defective areas of the cartilage aiming to fill these areas and restore the 
smooth surface as before. Chondrocytes are collected from the same patient from a 
non-weight bearing area. These are then allowed to grow in an in vitro culture media. 
Lastly, they are implanted into the cartilage defects under a cover of the periosteal 
membrane (1st generation, ACI-p); under a collagen type I/III membrane (2nd 
generation, ACI-c); or into a scaffold matrix (3rd generation, ACI-m). Usually, this 
technique is reserved to areas of confined and localized cartilage loss; this is usually 
seen in young patients who had joint trauma. Patients with advanced OA and wide 
areas of cartilage loss didn’t show promising results with this technique [69]. Magnetic 
resonance imaging confirmed a better filling of small chondral defects when done by 
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a graft technique than by any other technique. This technique is also less likely to 
produce osteophytes [70].  
Carpometacarpal or trapeziometacarpal OA is a unique situation necessitating 
different surgical techniques, usually including trapeziectomy with or without ligament 
reconstruction and tendon interposition [71]. Interpositional arthroplasty and joint 
replacement are other modalities used for this type of OA. Comparative studies for 
the outcomes of those different procedures didn’t show any advantage for one 
technique over the others.  
The demonstration of different treatment modalities, pharmacological and surgical 
ones, aims mainly to clarify the limitations that exist for current therapeutic modalities. 
Pharmacological modalities aren’t specific enough to spare the anti-inflammatory 
pathways, and surgical ones aren’t showing significant preference over the 
pharmacological ones. This justifies our search for more accurate understanding of 
this disease and for new therapeutic targets and accurate medications.  
1.5 Prostaglandins:  
PG’s are a family of physiologically active lipid compounds that are involved in many 
physiological and pathological processes all over the body. One of their major roles is 
in inflammation. PG’s can be both inflammatory and anti-inflammatory mediators. In 
this respect they are involved in the OA pathological process. The synthesis of PG’s 
starts with the release of AA from the cell membrane, a reaction catalyzed by 
phospholipases. The next reaction is catalyzed by a COX that leads to the 
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intermediate PGH2 from AA. Two isoforms of COX are known, COX-1 which is 
constantly expressed, and COX-2 which is induced by inflammatory mediators [72]. 
The unstable PGH2 is then metabolized into more bioactive forms of PG’s like PGE2, 
PGD2, PGF2α, PGI2, and thromboxane A2 by different synthases [73].  Figure 3 
shows the pathways involved in the synthesis of different PG’s from AA. 
 
Figure 3: The synthesis of different PG’s from AA acid by COX and different PG 
synthases. 
Image source: http://vascular.free.fr/cox-pathway.jpg 
PG’s act via specific G protein-coupled receptors. Each prostaglandin acts via 
multiple different receptors subtypes and these receptors can cross react together. 
Via these multiple receptors PG’s can multiply their coupling capacity to different 
signal transduction pathways leading to a more diverse range of downstream effects. 
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These effects can occur in functionally opposing directions within the same cell. 
PGE2 for example is widely expressed in the CNS. It has 4 receptors subtypes giving 
it a diverse functionality even inside the same cell. PGE2 can have 
neurodegenerative or neuroprotective effects depending on which receptor it binds to. 
In articular cartilage, PGE2 plays a degenerative role. It inhibits proteoglycans 
synthesis, which are one of the main components of healthy cartilage. PGE2 also 
induces matrix metalloproteinase 13 (MMP13) and aggrecanase 5 (ADAMTS-5), 
which degrade cartilage proteins. The main effect of PGE2 on articular cartilage is 
mediated through a receptor known as EP4 [74].   
Among different PG’s, PGD2 is an interesting one. It’s synthesized from PGH2 by 
PGD synthase and then gets enzymatically dehydrated into 15d-PGJ2. 15d-PGJ2 is 
the natural endogenous ligand of peroxisome proliferator-activated receptor gamma 
(PPAR-γ) nuclear receptor and transcription factor. PPAR-γ among other functions, is 
known to suppress inflammatory cytokines like COX-2, IL-1β, TNF-α, inducible nitric 
oxide synthase (iNOS) MMP1, MMP13 [75]. This function was tested with synthetic 
ligands of PPAR-γ before discovering 15d-PGJ2 [75]. This makes 15d-PGJ2 (and 
thus PGD2) one of the most important natural anti-inflammatory PG’s.  
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1.6 PGD2:  
Many studies suggested a protective role for PGD2 in OA [73] [76]. Indeed, treating 
chondrocytes with PGD2 increases the production of collagen type 2 and aggrecan, 
which are involved in cartilage repair [77]. In addition, chondrocytes treated with 
PGD2 showed lower rates of cell death [76]. PGD2 has also a role in inhibiting the 
production of matrix metalloproteinase 1 and 13, which are involved in cartilage 
damage [78]. In light of these observations, it is noteworthy that studies noted 
increased levels of PGD2 during the resolution phase of the inflammation process. 
These high levels of PGD2 were lost by the use of COX-2 inhibitors suggesting a role 
for COX-2 in activating anti-inflammatory pathways [79]. Further exploring and 
confirming the role of PGD2 as anti-inflammatory, in vivo studies using PGD2 
synthase knockout mice showed a failure of resolution of inflammation [80]. Another 
study confirmed the anti-inflammatory role of PGD2, using the delivery of PGD2 
synthase into a murine air pouch model of monosodium urate monohydrate crystal-
induced inflammation via a retroviral method [81]. PGD2 has two main receptors, D 
Prostanoid receptor (DP1) and chemoattractant-receptor-like molecule (CRTH2), also 
known as (DP2) [82]. Activation of the DP1 pathway is the one responsible for the 
down-regulation of MMP 1 & 13 in chondrocytes [78]. PGD2 exhibits its anti-
inflammatory effect through its potent anti-inflammatory end product 15d-PGJ2 (15-
deoxy-delta12, 14-PGJ2) [83]. 15d-PGJ2 has a significant anti-arthritic effect through 
downregulation of inflammatory mediators of OA [83]. This includes IL-1β, tumor 
necrosis factor-alpha (TNF-alpha), iNOS, and MMPs 1 and 13 [83]. 15d-PGJ2 
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induces its effect through nuclear PPAR-γ [83, 84] as well as other pathways 
independent of PPAR-γ [84].  
PPAR-γ is a nuclear receptor protein that works as a transcription factor for different 
genes including anti-inflammatory genes. This receptor is noticeably downregulated in 
osteoarthritic cartilage in vivo and was downregulated also in chondrocytes treated 
with IL-1β in vitro [85]. This down-regulation is interfering with the PGD2 protective 
function. PPAR-γ has a wide range of functions, besides being a potent anti-
inflammatory effector through suppression of the previously mentioned mediators; it 
plays also a role in reversing insulin resistance. Studies found that PPAR-γ decreases 
insulin resistance and improves liver handling of glucose by upregulating insulin 
receptors [86], from which appeared the thiazolidinediones family of drugs as insulin 
sensitizers to treat type 2 diabetes. PPAR-γ also plays a key role in adipogenesis, 
therefore, PPAR-γ antagonists have been used to decrease steatosis and adipose 
tissue formation [87] [88].     
1.7 L-PGDS:  
PGD2 is formed from PGH2 by a PGD synthase. There are two isoforms of PGD 
synthase, lipocalin PGDS (L-PGDS) which is glutathione-independent and 
hematopoietic PGDS (H-PGDS) that is glutathione-dependent [89]. L-PGDS has a 
wide distribution all over the body especially within the central nervous system [90, 
91], heart [92], retina [93], genital organs [94], and chondrocytes [95]. H-PGDS shows 
abundance mainly in hematopoietic tissues, mast cells [96], megakaryocytes [97], 
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and T-helper lymphocytes-2 [98]. Figure 4 explains the distribution of L-PGDS and H-
PGDS in different tissues. 
 
Figure 4: PGDS distribution in body tissues. 
L-PGDS has a dual function; enzymatic as well as non-enzymatic. Figure 5 describes 
its known functions. Enzymatically, it synthesizes PGD2 from PGH2. Non-
enzymatically, it acts as a transmembrane transporter protein for small hydrophobic 
molecules including PGD2, protecting it from metabolism and non-enzymatic 
dehydration into PGJ2. Also, PGDS has lipophilic ligand-binding properties by which it 
binds retinoid, thyroid hormones, and bile pigments including bilirubin and biliverdin. 
PGDS increases in cerebrospinal fluid (CSF) after subarachnoid hemorrhage to act 
as a scavenger for bilirubin. It plays a role also in cell migration and morphological 
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changes mainly through retinoid. Lipophilic ligand binding properties of this protein 
contribute to its anti-cancer function, as many lipocalin-ligands (like retinoid) are 
known to be involved in cell cycle regulation and cell proliferation. The main 
mechanism of this function is not fully deciphered yet.  
 
Figure 5: L-PGDS function. 
The three-dimensional structure of L-PGDS is formed of 9 β-Strands and 3 α-helices. 
They are labeled A-I and 1–3 respectively in Figure 6. L-PGDS is formed of 190 AA 
giving it a calculated MW of 21 kilodalton (KD). Though, it actually appears at a MW 
range of 25 to 37Kd. This is because of the post-translational modification of the 
protein, as this protein has multiple glycosylation and phosphorylation sites giving it a 
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wide range of MW and functionality according to which site is phosphorylated and 
which is glycosylated [99]. It has an enzymatic active site, at cysteine 65 (Cys65), an 
important glycosylation site at asparagine 51 (Asn51), and an important 
phosphorylation site at serine 106 (Ser106) [99].  
 
Figure 6: L-PGDS 3D structure. 
Image source: http://urade.wpi-iiis.tsukuba.ac.jp/research/analysis.php 
Depending on L-PGDS location inside the cell or in body fluids, different modified 
isoforms of L-PGDS appear. This is very important because it indicates that L-PGDS 
is modified in different ways to adapt for its multiple functions and in different 
locations also. For the purpose of using L-PGDS as a therapeutic target, we need to 
identify exactly the enzymatically active form to use as a medication avoiding the side 
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effects that may arise from other forms. These post translational modifications 
suggest different functions for different L-PGDS isoforms.  
L-PGDS is the key regulatory enzyme for PGD2 production from PGH2 therefore; it is 
the key regulatory enzyme for 15d-PGJ2 production also. This makes the regulation 
of L-PGDS production in chondrocytes the key for the regulation of natural anti-
inflammatory pathways. The pathway we are working on in this study is described in 
Figure 22 and explained in details in the discussion.  
1.7.1 In the joint:  
New studies started exploring the roles played by L-PGDS and H-PGDS as well as 
their regulation in cartilage. Higher abundance for L-PGDS mRNA and protein of 
about 20 fold was found in normal and osteoarthritic chondrocytes compared to H-
PGDS [100]. L-PGDS is suggested to have a protective role in chondrocytes 
considering its end product, PGD2. Pursuing this protective role, L-PGDS is 
expressed at higher levels in many pathological conditions. Among these conditions, 
multiple sclerosis [101], atherosclerosis and coronary artery diseases [92], diabetes 
mellitus [102], and hypertension [103]. An interesting study by Zayed et al. in 2008 
showed a key role for IL-1β in the induction of L-PGDS, both at the mRNA and protein 
levels, in chondrocytes, in a dose and time-dependent fashion. This eventually led to 
higher levels of PGD2.  
The increased levels of L-PGDS mRNA and protein were confirmed to be through 
gene induction. Different pathways were studied to identify those involved in L-PGDS 
gene induction. The successful blocking of IL-1β induction of L-PGDS using 
30 
 
 
translation inhibitors like cycloheximide, C-jun N-terminal kinase (JNK), NF-κB, p38 
MAP kinase and Notch, confirmed the involvement of these pathways in L-PGDS 
gene induction by IL-1β [100]. Interestingly, inhibition of the extracellular signal-
regulated kinase/mitogen-activated protein kinase (ERK/MAPK) pathway didn’t show 
any significant effect on blocking the induction of L-PGDS by IL-1β [100]. The end 
product PGD2 was found to have a negative feedback inhibitory effect on L-PGDS 
induction by IL-1β in chondrocytes [100].  
1.7.2 In the central nervous system:  
L-PGDS is a major protein and it has many roles. It is used as a biomarker in patients 
with idiopathic normal pressure hydrocephalus (iNPH), a degenerative disease 
characterized by progressive dementia, gait problems and urinary incontinence. L-
PGDS level is decreased in patient with iNPH, indicating the death of arachnoid cells 
responsible for its production. In the same disease, it plays a role as a scavenger of 
amyloid beta (Aβ) which has a neurotoxic effect leading to Alzheimer's disease, a 
major comorbid condition of iNPH [104]. Multiple sclerosis (MS) is an autoimmune 
disease leading to multifocal, recurrent, demyelination of the white matter of the 
central nervous system. L-PGDS generally plays a protective role in the CNS. In 
multiple sclerosis where there are plaques of degenerated myelin sheaths from the 
autoimmune process responsible for the pathology of the disease; L-PGDS is present 
at high levels in oligodendrocytes and astrocytes in the shadow plaques of MS. This 
is in contrast with other places within the white matter where there are no MS 
plaques, and at the same time of white matter from normal individuals. The observed 
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increased production of L-PGDS is a stress response in those cells and was not 
found to happen in parallel in the CSF itself [101]. L-PGDS also acts as a scavenger 
of Biliverdin in the CSF in cases of subarachnoid hemorrhage (SAH) [105]. Biliverdin 
is a metabolite of hemoglobin which is released from red cell corpuscles after their 
hemolysis in cases of subarachnoid hemorrhage. Hemolysis is due to low CSF 
osmolarity.  
1.7.3 In the cardiovascular system:  
In the cardiovascular system and in atherosclerosis particularly, L-PGDS plays a role 
as a marker for coronary artery diseases. This was based on particular findings 
linking degree of atherosclerosis with the levels of L-PGDS. In atherosclerosis, higher 
levels of PGE1 and its key enzyme “microsomal prostaglandin E synthase-1” 
(mPGES-1) and lower levels of PGD2 and its key enzyme (L-PGDS) were found in 
symptomatic plaques [77]. The opposite was found in asymptomatic plaques [77]. 
This suggests that a balance exists between those two types of PG’s upon which the 
pathology of the disease predominates [77]. This also suggests that the shift towards 
PGD2 may have a protective function in different tissues. Most recent studies used 
blood tests to detect L-PGDS levels in patients with different degrees of 
atherosclerosis and coronary artery disease. These studies were aiming to use L-
PGDS serum levels as a diagnostic marker for the severity of atherosclerosis or a 
predictive tool of the probability and severity of coronary artery disease. Authors 
concluded that there were no significant differences in serum levels of L-PGDS 
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between different patients, suggesting a poor diagnostic value for L-PGDS level in 
atherosclerosis generally and coronary artery diseases specifically [106].  
1.7.4 Reactive oxygen species (ROS):  
Considering the fact that ROS activate Nuclear factor erythroid 2-related factor 2 
(Nrf2) [107] and that Nrf2 induces L-PGDS by a recognized binding site for Nrf2 on 
the L-PGDS promoter region [108], it is reasonable to assume that ROS can induce 
L-PGDS in chondrocytes. This is part of a salvation pathway to protect chondrocytes 
against oxidative stress. Based on this hypothesis, ROS generators hydrogen 
peroxide (H2O2) and tert-butyl hydroperoxide (4BHP) were included in this study to 
determine their effect on L-PGDS expression levels. Fukuhara, et al. in 2012 [109] 
had shown an anti-apoptotic effect for L-PGDS in neuronal cells where L-PGDS was 
induced in neuroblastoma cells by oxidative stress using H2O2 (0, 50, 100 μM) for 
24H. L-PGDS levels were increased in a dose-dependent manner and cell viability 
assays showed decreased cell death with a direct correlation to the level of L-PGDS. 
They noticed that the Thiol group at Cys65 of L-PGDS got oxidized into sulfonic acid 
after treating neuroblastoma cells with H2O2. This suggested a ROS scavenger 
function for L-PGDS. These results were obtained by measuring the MW of L-PGDS 
before and after H2O2 treatment using MALDI-TOF (matrix-assisted laser desorption 
ionization - time of flight) mass spectrum. H2O2-treated L-PGDS proteins showed a 
32Da higher MS difference.  
The structure of L-PGDS is composed of 9 stranded antiparallel β-sheet folded on 
itself to form a hydrogen bonded β-barrel and α-helix [110]. Human L-PGDS have two 
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thiol groups Cys65 and Cys167. Cys65 is the active catalytic domain of the enzyme 
[111]. Thiol groups had been found to react with different reactive O2 species and 
thus scavengers those harmful radicals, making those thiol groups key players in cell 
defense against free radicals [112, 113]. This suggests that the L-PGDS scavenger 
function also protects the cells against inflammation along with its role in the 
production of PGD2. L-PGDS also functions as lipid transporter [114] which is not 
affected by H2O2 treatment, as its binding capacity to lipophilic molecules was the 
same before and after treatment [109].  
1.7.5 Nrf2:  
Kim et al. in their study in 2013 [108] showed a role for Nrf2 in L-PGDS induction by 
PGD2. In bone marrow-derived macrophages, PGD2 showed a positive feedback 
effect on L-PGDS gene induction, increasing its expression through activation of Nrf2, 
a well-known antioxidant transcription factor [108]. A specific binding site for Nrf2 was 
identified on the promoter region of L-PGDS gene. This paper concluded a positive 
feedback effect for PGD2 on L-PGDS gene induction in macrophages. 
Kim et al. didn’t use a blocker of Nrf2 to confirm its involvement in PGD2 mediated 
induction of L-PGDS gene but instead they used an Nrf2 Knockout (KO) mice 
approach to address this issue. This approach failed to induce L-PGDS gene in 
macrophages of KO mice treated with PGD2. Further confirming this role, 
macrophages from KO mice were transfected with Nrf2 which restored the lost 
response [108]. Nrf2 is normally latent within the cells until it gets activated by one of 
its activators, usually oxidative stressors. At that point, Nrf2 migrates to the nucleus 
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and binds to promoter regions of specific genes known as the antioxidant response 
element (ARE). These genes are the master regulators of the whole antioxidant 
system in cells. Nrf2 is mainly activated through free radicals, other activators were 
found to be involved also, PGD2 for example [108]. Studies have shown a higher 
antioxidant protective effect by induction of intrinsic antioxidant pathway through Nrf2 
compared to the use of exogenous antioxidants like vitamin C or E [115]. This makes 
Nrf2 and its agonist’s potential therapeutic targets in OA, both for the Nrf2 role in L-
PGDS induction and in activating intrinsic antioxidant pathways (ARE). 
Infection and inflammation induce oxidative stress in cells and increase the 
production of ROS. Cells then activate their natural antioxidant system to maintain 
cell homeostasis. Nrf2 is a key transcription factor for the genes of ARE.  
In normal conditions, Nrf2 is found bound to Kelch-like ECH-associated protein 1 
(Keap1) which in turn is bound to actin in the cytosol. Keap1 promotes binding of 
Cul3-dependent E3 (Cul3) ubiquitin ligase complex to Nrf2 as a part of a post-
translational modification of the protein. This leads to Nrf2 degradation under normal 
conditions making its half-life around 13-21 minutes [116, 117]. This keeps cellular 
Nrf2 levels relatively low. Keap1 is rich in the amino acid cysteine which makes it 
works as a sensor for the redox status of the cell.  
Under oxidative stress, intracellular ROS and electrophiles increase leading to 
increasing oxidation of Keap1 cysteine residues (C151, C273, C288, C613) that limits its 
activity as a bridge binding ubiquitin ligase complex to Nrf2 and thus limits its role in 
Nrf2 degradation. Here Nrf2 half-life extends to 100-200 minutes [117]. Once Nrf2 is 
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released from the Keap1 complex, and survives degradation, it migrates to the 
nucleus where it plays its role as a transcription factor for ARE genes [118]. Nrf2 
binds to promoter regions of many cytoprotective genes including L-PGDS, as 
recently a Nrf2 binding site was identified on the promoter region of L-PGDS gene as 
explained before [108]. Figure 7 explains the Nrf2 pathway and the role of ROS in its 
function.  
 
Figure 7: Nrf2 pathway and role of ROS in its activation. 
ROS leads to oxidation of cysteine residues on Keap1 leading to loss of its function as a bridge for ubiquitin. This 
leads to longer t1/2 for Nrf2 which then migrates to the nucleus and binds to promoter regions of the ARE genes. 
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A recent study in 2013 used coffee alkaloid trigonelline (trig) as an inhibitor of Nrf2 
pathway in pancreatic cancer cells to block its protective effect and its anti-apoptotic 
effect. They had promising results controlling cancer growth [119]. Estrogen-related 
receptor beta (ERRβ) is a family of nuclear receptors that were found to block the 
Nrf2 pathway, particularly the (SFhERRβ) member of this family [120]. Nrf2 siRNA 
can also be used to silence this transcription factor to test its involvement in IL1-β 
induced L-PGDS [121].  
To summarize, PGD2 had a positive feedback on L-PGDS induction through Nrf2, so 
it may activate the intrinsic ARE as well as Nrf2. This suggests that PGD2 can 
contribute to anti-inflammatory actions in two different ways, through 15d-PGJ2 or 
Nrf2 induced ARE. Nrf2 has a specific binding site on L-PGDS gene promoter region 
and induces it in macrophages. This opens the door for the hypothesis that the Nrf2 
pathway may be involved in L-PGDS induction in chondrocytes also. IL-1β has a 
known role as an inflammatory mediator in many tissues including chondrocytes. It 
induces many inflammatory pathways including those producing free radicals, the 
main activator of Nrf2. This may explain the mechanism by which IL-1β induces L-
PGDS, through Nrf2.  
1.7.6 Objectives and rationale:   
15d-PGJ2 is a major anti-inflammatory PG. It works through PPAR-γ to downregulate 
major inflammatory genes like MMP1, MMP13, iNOS, TNF-α, IL1β and COX-2. 15d-
PGJ2 is formed by a dehydration reaction from PGD2. PGD2 is formed by PGDS 
from PGH2, the main precursor for all PG’s. PGH2 is in turn formed from AA by the 
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COX enzyme. This makes PGDS the rate-limiting step for 15d-PGJ2 synthesis and so 
for a major intrinsic anti-inflammatory pathway. Figure 22 explains this pathway in 
details. Considering the abundance of L-PGDS versus H-PGDS in chondrocytes, both 
normal and OA, we are focusing in this study on L-PGDS. Therefore, the main 
objective of this study is to understand the regulation of L-PGDS expression in 
chondrocytes. We are aiming in this study to identify chondrocytes’ response to 
different inflammatory conditions in vivo and in vitro, regarding L-PGDS. To do so, we 
are going to analyze the effect of IL-1β and interleukin 17 (IL-17) (as inflammatory 
cytokines), as well as H2O2 and 4BHP (as ROS generators) on L-PGDS expression 
levels in human chondrocytes in vitro. ROS generators are used in this study for two 
main reasons, first, ROS induce inflammation and second, ROS increase the half-life 
of Nrf2 and so enable its translocation into the nucleus to express ARE genes (see 
Figure 7). Considering that Nrf2 has a binding site on L-PGDS gene promoter region 
and plays a role in its regulation as explained before, among our objectives is to study 
the effect of ROS generators on L-PGDS expression levels. In vivo also, we are going 
to analyze L-PGDS expression levels by chondrocytes in mice OA models, both 
surgically induced and naturally induced (by aging), using immunohistochemistry 
techniques.    
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Chapter 2: Materials and 
Methods
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2.1 Destabilization of medial meniscus surgery:  
The destabilization of medial meniscus (DMM) surgeries were done in 10-12 weeks 
old male mice, strain C57BL/6, to induce an OA model. These mice were sacrificed at 
8 weeks of ages post-operatively; this time selection was based on observations from 
previous work done in our lab for the time needed to develop OA post DMM. Their 
knees were examined for OA changes histologically and for L-PGDS expression by 
immunohistochemistry. 
The medial meniscus is fixed to the tibial plateau by the medial meniscotibial ligament 
(MMTL). A 3 mm longitudinal incision was made on the distal side of the patella with a 
# 15 blade exposing the joint capsule. The joint capsule was then opened by micro-
iris scissors and a dissection was performed on the meniscotibial ligament. MMTL 
was dissected in a proximo-lateral direction with a micro-surgical knife. This led to the 
destabilization of the medial meniscus which eventually led to a medial displacement 
of the meniscus. The joint capsule was then closed by continuous sutures using 8-0 
Vicryl®, and for the subcutaneous tissues and skin 7-0 Vicryl® was used. Sham 
surgeries were performed in animals following the same steps without dissecting the 
meniscotibial ligament.  
2.2 Aging associated OA: 
We followed the normal aging process in a large number of mice to determine the 
spontaneous appearance of OA compared to the DMM model. We sacrificed the mice 
and collected their knees at 3 or 18 months of age; this was also based on 
observations from previous work done in our lab for aging associated OA. Our aim 
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was to obtain knee joint samples at different age points to study the changes in the 
articular cartilages, bones, synovial membranes, genes and proteins at different time 
points.  
2.3 Histology:  
Histology blocks were made in collaboration with other labs at Notre Dame Hospital. 
Blocks were cut using Leica® rotary microtome into 5 micrometers slices. They were 
then put on histology glass slides, and kept in the incubator for 48h at 37°C. 
For histological staining we used a protocol of different washing and staining steps, in 
which the slides were processed as follow:  
First we washed the slides in Xylene for 5 minutes twice. The slides were then 
washed again in ethanol 100% for 3 minutes twice. Then, one more wash with double 
distilled water (ddH2O) for 2 more minutes.  
Slides were then stained with hematoxylin weigert 50% (Sigma-Aldrich®) for 4 
minutes, then washed in ddH2O for 2 minutes, incubated in ferrous chloride for 1 
minute, and finally washed in ddH2O for 2 more minutes.  
Fast green staining (Sigma-Aldrich®) was done by incubating the slides in the dye for 
30 seconds, then in acetic acid 1% for 5 seconds, followed by safranin-O (Sigma-
Aldrich®) for 4 more minutes.  
The final step was washing the slides with ethanol 100% for 1 minute, 3 times and 
then xylene for 2 minutes, two times. Slides were ready at that point and were 
covered with glass cover slips and glued.   
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2.4 Immunohistochemistry:  
For immunohistochemistry, we washed the slides in Xylene for 5 minutes, 3 times and 
then in ethanol for 5 minutes, 3 more times (at concentrations of 100%, 95% and 
75%). A final wash was performed in ddH2O for 1 minute twice. The sections on the 
slides were then marked with histology PAP pen (Abcam®), incubated with one drop 
on each section of peroxidase (Dako®) for 10 minutes at room temperature on a 
humid rack. This last step was the 1st blocking step. Slides were then washed with 
ddH2O for 1 minute, twice. They were then blocked again with 50µl of 1% BSA for 1h 
at room temperature. The 1st antibody was then incubated with the slides overnight 
(O/N) at 4°C in BSA 1% at different concentrations. For L-PGDS, the concentration 
was 1:100. Slides were then prepared for day 2 where they were washed in ddH2O 
for 1 minute twice, and then 1 drop of biotinylated link antibody (Dako®) was added to 
each slide for 30 minutes at room temperature. Slides were then washed again in 
ddH2O for 1 minute twice. Streptavidin HRP was added to each slide for 1 hour at 
room temperature. Another wash cycle was done. For the next step we prepared a 
diaminobenzidine (DAB) solution (Dako®), as 1 drop of DAB in 1ml of its buffer in a 
dark Eppendorf. The DAB solution forms a brown stain in peroxidase-based 
immunohistochemical reactions. We added 1 drop of the DAB preparation to each 
section and followed the change of the color under the microscopy. Once the tissues 
get the DAB brown stain we stopped the reaction by washing the slides in ddH2O to 
avoid oversaturation of the signal. Lastly, the slides were counterstained with Eosin. 
Slides were washed in ddH2O for 1 minute 4 times, then in 80% ethanol for 30 
seconds, and then stained with Eosin for 2 seconds. Slides were then washed in 
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100% ethanol 3 times (5 minutes, 3 minutes and another 3 minutes). Lastly, they 
were washed in xylene for 2 minutes, after which we glued the slides with a glass 
cover. Each group of slides was treated under the same conditions and for the same 
periods so we can compare the results from different slides in the same group and 
within different groups. Expression levels of L-PGDS were quantified by counting cells 
stained with the DAB brown stain versus the total number of cells per high power 
microscopic field. This counting was done with at least 3 slides for each condition 
tested and the median of each condition was taken. The medians were compared in 
aged versus young mice, and in DMM versus the sham surgery group to quantify the 
increase in L-PGDS expression.   
2.5 Cartilage collection & Chondrocyte culture:  
Knee specimens were collected from patients undergoing joint replacement on the 
same day of operation or 1 day after. Normal knee specimens were collected from 
cadavers shortly after death. Synovial fluid samples were collected from patients with 
OA and normal subjects. All specimens were kept at 4°C until digestion to ensure the 
viability of chondrocytes. 
Cartilage pieces were cut from the knees under aseptic conditions and kept them in 
cold sterile Phosphate buffered saline (PBS). The cartilage pieces were then washed 
twice with sterile PBS then kept in (penicillin/streptomycin) 5X in PBS for 1 hour at 
room temp. Cartilage pieces were then washed again twice with regular sterile PBS 
(without antibiotics), to remove any traces of the antibiotics. We started then digesting 
the cartilage pieces by incubating them in Pronase 1mg/ml in DMEM+ 10% FBS+ 1% 
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P/S Sigma-Aldrich® in a water bath at 37° for 1 hour with gentle agitation. Cartilage 
pieces were then washed with warm (37°C) sterile PBS twice. A collagenase 
digestion was then performed using 600units/ml or 2mg/ml of collagenase type I 
(Sigma-Aldrich) following its addition to the cartilage pieces for 5 hours incubated at 
37°C in a water bath with gentle agitation. The fluid (containing chondrocytes) was 
then collected into 50ml falcon tubes and centrifuged at 1500 revolutions per minute 
(rpm) for 10 minutes. The supernatant was discarded, cells were re-suspended in 
DMEM 10% FBS 1% P/S, then seeded into a 175ml flask. The flasks were then 
incubated at 37°C in humidified 5% CO2 incubator, for 2 weeks until they reach full 
confluence. The remaining cartilage pieces were then digested one more time by 
applying 50% diluted collagenase from the previous preparation, incubated at 37°C in 
a water bath with agitation O/N. The digestion fluid then went through the same 
previous steps to collect 2nd day chondrocytes and seed them into another 175ml 
flask. Both flasks were incubated for 2 weeks until they reached full confluence. 
Chondrocytes were then collected from the 175ml flask by trypsinization using 5ml 
trypsin 0.05% Multicell® per flask and kept in the incubator for 5 min. After the 5 
minutes, the trypsinization reaction was stopped by adding 10ml DMEM media 
containing 10% FBS and 1% P/S. The fluid was then centrifuged at 1500rpm for 10 
min, cells were re-suspended in different volumes of DMEM 10% FBS 1% P/S 
according to the final cell count needed per ml. After counting cells, they were seeded 
into 6 well plates at a density of 750,000 cells per well in 2ml media or into 12 well 
plates at a density of 250,000-300,000 cells per well in 1ml media. Cells were left 24h 
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to attach to the wells and then serum starved in a media containing 1% FBS for 
another 24h. At that point, chondrocytes were ready to be treated.  
Chondrocytes were treated with: 
• IL-1β (an inflammatory cytokine) at different concentrations from 0-600pg/ml 
for 48h, or at 100pg/ml for time course assays.  
• IL-17 (also an inflammatory cytokine) at different concentrations from 0-
100ng/ml for 48h, or at 50ng/ml for time course assays. 
• H2O2 (as a ROS generator) at different concentrations from 0-50µM/ml for 48h 
(re-added every 24h due to its instability), or at 20µM/ml for time course 
assays, (re-added also every 24h).  
• 4BHP (also a ROS generator) at different concentrations from 0-50µM/ml for 
24h and 48h, or 20µM/ml for time course assays.  
For cell lysis, we removed the growth media from the plates from the previous step 
and washed the cells with cold sterile PBS 1ml/well twice. We then lysed the cells 
with a lysis buffer composed of Tris 20mM PH7.4, NaCl 150mM, EDTA 1mM PH 7.4, 
PMSF 1mM, protease inhibitors at concentration 1µg/ml and SDS 0.5% in double 
distilled water using 200µl/well for the 12 wells plates, or 400µl/well for the 6 well 
plates. The cells were incubated with the lysis buffer for 10min at room temperature 
with gentle shaking. Samples were then collected in Eppendorf tubes and sonicated 
for 10sec on ice. The lysate was then centrifuged at 13,000 rpm for 5min. Proteins 
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from the supernatant were then quantified by Pierce™ BCA Protein Assay Kit from 
Life technologies® according to the manufacturer’s instructions.   
2.6 Western Blotting (WB):  
To detect L-PGDS produced by the chondrocytes, we used 20µg of the cell lysate 
protein per sample and added 5µl sample buffer (10X) to it; the total volumes were 
then equalized with lysis buffer to 50µl. The samples were heated for 2 minutes at 
95ºC, left to cool down, and then loaded into 12% acrylamide gel to get separated.  
To detect L-PGDS released by the chondrocytes in vitro, we used 45µl per sample of 
the growth media of the treated chondrocytes. We added 5µl of the sample buffer 
(10X) to each; the samples were then processed as above. 
To detect L-PGDS released by the chondrocytes in vivo, we used 20µl of the synovial 
fluid per sample plus 5µl of the sample buffer (5X) for each; and then processed as 
above. 
Lastly, we used 1µl of the CSF as a positive control and we added 5µl of the sample 
buffer (10X) also; total volumes were then equalized to 50µl and processed as above. 
We used 12% sodium dodecyl sulfate SDS-page gel for better separation of this small 
MW protein (L-PGDS). Gels were prepared in our lab. Proteins were transferred to 
nitrocellulose membrane (Bio-Rad®) after migration on the gel.  
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Antibodies used: 
• L-PGDS, (US-Biological®), at the concentration recommended by the 
manufacturer. For Immunohistochemistry 1:100, for WB 1:1000 with O/N 
incubation at 4ºC. 
• B-actin, (Santa Cruz biotechnology®) at a concentration of 1:200. 
• iNOS and COX-2 were from Cayman chemicals®, both used at a 
concentration of 1:1000 for WB. 
• The 2nd antibody was a goat anti-rabbit IgG coupled to horseradish peroxidase 
(HRP). This was used for all the primary antibodies and was bought from 
Cayman chemicals®. The 2nd antibody was used at a concentration of 
1:10,000 for 1 hour at room temperature. 
Nitrocellulose membranes were incubated O/N with the 1st antibody at 4°C then 
washed with TTBS wash buffer for 6 times, 10 minutes each. Then, they were 
incubated with the 2nd antibody at room temperature for 1h, and again washed 6 
more times, 10 minutes each. Developing the membranes was done by the super-
signal developing agent (Thermo scientific®) using the Bio-Rad® Chemidoc® 
imaging system.  
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Chapter 3: Results 
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All the experiments in this section were performed at least 3 times, and the results 
presented were consistent in at least 3 different experiments. 
1. Histological changes in aging-associated and surgically-
induced OA:  
To identify the pathological features of osteoarthritic cartilage either aging-associated 
or surgically induced, histological sections were compared from 3-month-old mice 
versus 18-month-old animals, and from 8-weeks post sham surgery mice versus 8-
weeks post DMM animals, respectively. Upon confirming the development of OA 
histologically, samples were used to test for L-PGDS expression. In aging-associated 
OA (Figure 8), we identified areas of cartilage loss, damage and fibrillation (arrow). 
These changes represent the main pathological features of OA that can be 
histologically identified. Figure 9 shows area of cartilage loss (arrow), using lost 
Safranin-O staining in surgically induced OA animals compared to the sham surgery 
group.   
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Figure 8: Histological changes in aging-associated osteoarthritis. 
 
 
 
 
 
 
 
 
Figures 8 and 9: Safranin-O was used to stain the proteoglycans in cartilage so we 
could visualize the articular cartilage versus the surrounding tissues which were 
Figure 9 Histological changes in surgically induced OA. 
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stained green by ‘fast green stain’. The red coloration indicates proteoglycans in 
cartilage. 
2. Expression of L-PGDS in aging-associated and surgically-
induced OA: 
We investigated the expression levels of L-PGDS in vivo in aging-associated as well 
as in surgically-induced OA by immunohistochemistry. For aging-associated OA, L-
PGDS expression levels were compared in 3-month-old mice versus 18-month-old 
animals in Figure 10, where we could see higher expression levels (2-3 folds) in the 
18-month-old mice.   
For surgically induced OA, mice which underwent DMM surgeries were compared to 
those with sham surgeries. Eight weeks post DMM or sham surgeries, knees were 
collected and put in paraffin blocks and slides were made for immunohistochemistry. 
L-PGDS expression levels were 3 folds higher in DMM-operated mice compared to 
sham-treated animals (Figure 11).  
These results indicate that chondrocytes increase their expression of L-PGDS in vivo 
in response to either age-associated OA or following surgically-induced OA.   
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Figure 10: Spontaneous age-associated OA. L-PGDS levels were higher in 18-
months-old mice compared to 3-months-old animals. The arrow indicates the 
pigmentation visualized using the Dako® kit. 
 
Figure 10 L-PGDS levels in spontaneous age associated OA - immunohistochemistry. 
3m old 18m old 
Negative control 
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Figure 11: DMM is a widely used surgery to induce OA models in knee joints. For the 
control mice, sham surgeries were done without cutting the knee ligaments or 
menisci. Knees were collected 8 weeks post-operatively from the 2 groups and 
expression levels of L-PGDS were detected by immunohistochemistry (IHC). In the 
negative control slides all the IHC steps were done without the use of the 1st antibody. 
In all experiments the concentration of the 1st antibody (L-PGDS) was 1:100 and the 
Dako® kit was used for the detection of the 2nd antibody. Pigmented cells were 
counted versus total number of cells in each slide to identify the percentage of stained 
cells. This was then used to compare the expression levels of L-PGDS in 3 month 
versus 18 months old mice and in DMM versus sham surgeries mice.  
Figure 11 L-PGDS levels in surgically induced OA - immunohistochemistry. 
DMM-operated knee 
8 weeks post-surgery 
Sham-operated knee 
8 weeks post-surgery 
Negative control 
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3. Expression of L-PGDS in chondrocytes treated with IL1β, 
dose-dependent and time course: 
• Dose-dependent treatment:   
IL-1β is a well-established inflammatory mediator [122] and widely used to induce 
inflammation in vitro. We previously showed that the levels of L-PGDS in 
chondrocytes treated with IL-1β increase in a dose and time-dependent manner 
[95]. We used different doses and different durations of treatment to achieve the 
optimal results. The new finding here is that treating chondrocytes with different 
inflammatory cytokines (IL-1β and IL-17) or ROS generators (H2O2 and 4BHP) not 
only increases L-PGDS expression but it also leads to the release of L-PGDS. The 
role of the released L-PGDS is not fully understood yet. Recent studies 
demonstrated that L-PGDS is a heavily glycosylated protein and each glycosyl 
group adds 3KD to the original protein MW. 
We identified L-PGDS in IL-1β treated chondrocytes cell lysate in a modified 
isoform of 37KD versus the original protein at 25KD, while we observed both the 
modified and non-modified isoforms in the growth media (Figure 12). We believe 
that different isoforms of L-PGDS do different functions in different locations, and 
also that they are produced in response to different stimuli.  
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Figure 12: Chondrocytes were treated with IL-1β in at concentrations ranging from 
25pg/ml to 600pg/ml for 48h. L-PGDS levels were detected in 20µg of the cell lysate 
and 40µl of the supernatant (growth media). CSF was used as a positive control in all 
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Figure 12: L-PGDS expression in IL1B treated chondrocytes dose curve.
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gels, as it is known to contain high levels of L-PGDS [123]. We used 0.5µl CSF per 
gel and L-PGDS was always detected at 25KD in all CSF samples. (X) Marks an 
empty well in all gels.   
• Time course treatment: 
To study the effect of prolonged exposure of chondrocytes to IL-1β, we performed 
multiple time points and dose response curves to adjust for the best results. During 
these experiments, we observed an increase in L-PGDS expression levels in a time-
dependent manner in the cell lysate as well as in the media. We further found that, in 
IL-1β treated chondrocytes, L-PGDS levels in the cell lysate increased steadily with 
treatment periods. We also found that L-PGDS in the cell lysate was detected at a 
MW of 37KD (the modified isoform), (Figure 13). In the supernatant (growth media), 
the non-modified isoform of L-PGDS was the prominent form observed compared to 
the response from the dose curve treatment experiments. This may suggest a shorter 
half-life for the modified isoform of L-PGDS. 
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Figure 13: Chondrocytes were treated with IL-1β 100pg/ml for different time periods 
ranging from 6h to 72h. L-PGDS levels were detected in 20µg of the cell lysates and 
40µl of the supernatants (media). CSF was used as positive control. (X) Marks an 
empty well.   
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Figure 13: L-PGDS expression in IL-1B treated chondrocytes time course. 
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4. Expression of L-PGDS in chondrocytes treated with IL-17, 
dose-dependent and time course: 
• Dose-dependent treatment:   
Our results suggest a weaker effect of IL-17 compared to IL-1β on L-PGDS 
expression levels and its release into the media. Indeed we couldn’t identify an 
increase in L-PGDS expression levels in chondrocytes cell lysates in response to 
IL-17 treatment. IL-17 treatment was still able to induce chondrocytes to release L-
PGDS into the media, in the non-modified isoform also. An interesting finding here 
was that L-PGDS levels in the media increased in a bell-shaped curve pattern, 
where they peaked at 20ng/ml IL-17 and then went back down again (Figure 14). 
 
 ng/ml 
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Figure 14: Chondrocytes were treated with IL-17 at concentrations ranging from 
1ng/ml to 100ng/ml for 48h. L-PGDS levels were detected in 20µg of cell lysate and 
40µl of supernatant (media). CSF was used as a positive control, (X) Marks an empty 
well.  
The results from the two previous Figures imply that chondrocytes under 
inflammatory situations try to activate their salvage pathways among which the 
induction of L-PGDS to produce PGJ2, a major anti-inflammatory component [124].  
• Time course treatment: 
While treating chondrocytes with IL-17 for different periods of time, the response was 
challenging as we didn’t initially have the expected results, especially that the dose 
curve was showing no increase in L-PGDS expression levels. At 50ng/ml, we started 
to have a response with the time course of IL-17 treatment. L-PGDS levels increased 
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Figure 14: L-PGDS expression in IL-17 treated chondrocytes dose curve. 
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in a bell-shaped curve also, peaking at 6h and O/N and then went back to almost 
basal levels at 48h. This actually partially explains why we didn’t observe a response 
with the dose curve (in the cell lysate) where all plates were incubated for 48h. Thus, 
no matter what was the dose of IL-17 used, at 48h L-PGDS levels were back at 
almost baseline. This may suggest a short half-life of L-PGDS. This may also be due 
to the loss of IL-17 effect after a few hours. IL-17 is usually stable and doesn’t need to 
be added every 24h like H2O2. So the expected effect of IL-17 is achievable mainly 
during the 1st few hours. L-PGDS was detected again in the modified isoform in the 
cell lysate. While, in the media we were able to observe a mild increase in L-PGDS 
expression levels (the non-modified isoform) that peaked at 48h and went back down 
to almost baseline at 72h (Figure 15).  
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Figure 15: Chondrocytes were treated with IL-17 50ng/ml for different periods of time 
from 6h to 72h. L-PGDS levels were detected in 20µg of the cell lysate and 40µl of 
the supernatant (media). CSF was used as positive control. (X) Marks an empty well. 
5. Expression of L-PGDS in chondrocytes treated with H2O2, 
dose-dependent and time course: 
• Dose-dependent treatment: 
Chondrocytes were treated with H2O2 and tetra butyl hydroperoxide to produce ROS 
within the cells to study the effect of ROS on L-PGDS expression levels. ROS 
generators were used because according to our hypothesis Nrf2 is involved in L-
PGDS gene regulation in response to ROS. We even hypothesized that this may be 
the same mechanism by which other inflammatory cytokines like IL-1β induce L-
PGDS. This hypothesis is based on a study that identified a binding site for the Nrf2 
0
0.5
1
1.5
2
2.5
zero 6h o/n 24h 48h 72h
L-PGDS IL17 time course 
Figure 15: L-PGDS expression in IL-17 treated chondrocytes time course. 
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transcription factor on the promoter region of L-PGDS gene in bone-marrow-derived 
macrophages (BMDM) [108]. Furthermore, researchers showed an increase in L-
PGDS expression levels in BMDM when they were treated with PGD2 (positive 
feedback regulation) by a mechanism involving Nrf2 [108]. This induction effect was 
lost in Nrf2 KO mice and re-established by the re-introduction of Nrf2 using a vector. 
H2O2 treated chondrocytes showed no obvious increase in the expression of L-PGDS 
in the cell lysates. In contrast, chondrocytes released L-PGDS into the media in a 
dose-dependent manner in response to H2O2 treatment. Again here, L-PGDS in the 
media was in the non-modified isoform and its levels were showing a bell-shaped 
curve pattern (Figure 16), while in the cell lysate L-PGDS was in the modified 
isoform.   
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Figure 16: Chondrocytes were treated with H2O2 in a concentration ranging from 
10µM/ml to 50µM/ml for 48h, and H2O2 was re-added every 24h due to its instability. 
L-PGDS levels were detected in 20µg of the cell lysate and 40µl of the supernatant 
(media). CSF was used as a positive control. (X) Marks an empty well. 
• Time course treatment: 
When chondrocytes were treated with H2O2 for different periods of time, we observed 
an increase in L-PGDS expression levels in treated cells versus control ones. This 
was also the case on the cell lysate level and for the modified isoform of L-PGDS. 
The expression of L-PGDS wasn’t steadily rising; instead, it mildly rose at 6h then 
stayed at that level through the rest of the time points. L-PGDS wasn’t detected in the 
media in all experimental time points with H2O2, (Figure 17). 
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Figure 16: L-PGDS expression in H2O2 treated chondrocytes dose curve. 
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Figure 17: L-PGDS expression in H2O2 treated chondrocytes time course. 
Figure 17: Chondrocytes were treated with 20µM/ml of H2O2 for periods of time 
ranging from 6h to 72h. Due to its instability, H2O2 was re-added every 24h to the 
media. L-PGDS levels were detected in 20µg of the cell lysate and 40µl of the 
supernatant (media). CSF was used as positive control. (X) Marks an empty well.  
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6. Expression of L-PGDS in chondrocytes treated with 4BHP, 
dose-dependent and time course: 
• Dose-dependent treatment: 
We used 4BHP as a ROS generator to induce L-PGDS in chondrocytes. 4BHP is a 
more stable ROS generator compared to H2O2; it can also induce cell death if the 
concentration is high or the duration of treatment is long enough. Because of that, we 
used 4BHP in small doses and for 24h of treatment only. Treating chondrocytes with 
4BHP caused an increase in L-PGDS expression levels in the cell lysates, as well as 
it led to the release of L-PGDS into the media in a dose-dependent fashion. The 
levels of L-PGDS in the media made a bell-shaped curve. L-PGDS was detected in 
the media mainly in the non-modified isoform while in the cell lysate it was in the 
modified isoform, (Figure 18). Interestingly, we observed a rise in the levels of the 
modified isoform of L-PGDS “in the media” concomitantly with the decrease of the 
same isoform in “the cell lysate” after 48h treatment with increasing doses of 4BHP 
(Figure 19). In these last experiments, cell death was observed in the form of 
detached and floating cells under the microscope. We didn't measure cell toxicity or 
apoptosis markers for the observed cells. Our observation of detached and floating 
cells may suggest that the modified isoform of L-PGDS is a potent oxygen free 
radicals scavenger, and it was the cells last line of defense against ROS before they 
died. It’s one of the well-known functions of L-PGDS to act as an oxygen free radicals 
scavenger through a thiol group in Cyc65 at its active site [109, 125].  
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It may also suggest that the modified isoform of L-PGDS is the most enzymatically 
active isoform. The only other time when we noticed the modified isoform of L-PGDS 
in the media was when chondrocytes were treated with IL-1β which can also generate 
ROS.  
These contradictory opinions underline the need for a further understanding of this 
protein post-translational modification and the role each isoform plays. Doing so, we 
will be able to identify the protective isoform and further target it with medications. 
This is further analyzed in the discussion.  
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Figure 18: L-PGDS expression in 4BHP treated chondrocytes dose curve 24h. 
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Figure 19: L-PGDS expression in 4BHP treated chondrocytes dose curve 48h. 
Figures 18 and 19: Chondrocytes were treated with 4BHP in a concentration ranging 
from 10µM/ml to 50µM/ml for 24h in Figure 18 and 48h in Figure 19. L-PGDS levels 
were detected in 20µg of the cell lysates and 40µl of the supernatants (media). CSF 
was used as a positive control. (X) Marks an empty well.   
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• Time course treatment: 
Treating chondrocytes with 20µM/ml of 4BHP for different durations lead to 
inconsistent results (data not shown). This was mainly because of the cell death that 
was observed at many points during the experiments. This was observed while 
increasing the dose or the duration of 4BHP treatment. Cell death made the 
preliminary results inconclusive for anything other than the rising of the levels of the 
modified isoform of L-PGDS in the media concomitantly with the decrease of these 
levels in the cell lysate. These findings were demonstrated in Figure 19. Reducing 
the dose of 4BHP to allow longer exposure of chondrocytes didn’t give any specific 
signal. Cell death was not measured here and no apoptosis markers were 
investigated. Cell death was just observed as detached and floating cells under the 
microscope. These observations were used only to adjust the dose of 4BHP and the 
duration of treatment, to study its effects without inducing cell toxicity or cell death.  
7. Expression of L-PGDS in synovial fluid: 
As we showed in previous results, chondrocytes release L-PGDS into the media for 
an unknown function (in vitro), in response to different inflammatory triggers. Aiming 
to detect the presence of this process in vivo, we examined synovial fluid samples for 
L-PGDS from different patients with or without OA. We found that L-PGDS is released 
by chondrocytes to the synovial fluid in vivo also.  Even more, both the modified and 
the non-modified isoforms of L-PGDS were detected in some cases (Figure 20). This 
particular result needs further investigation and a large numbers of samples to identify 
which conditions are associated with L-PGDS release in the synovial fluid and which 
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aren’t. Also to identify which isoform of L-PGDS is linked to which condition. This can 
be one of the future steps of this project.  
 
 
Figure 20: L-PGDS expression in synovial fluid samples 
In further experiments synovial fluids were treated with Hyaluronidase to enhance the 
detection of L-PGDS. 20µl of Hyaluronidase treated synovial fluid samples were used. 
CSF and plasma were used as a positive control. Samples were labeled with the 
patients code numbers, (OA) indicates a patient diagnosed with osteoarthritis while 
(N) indicates a non-osteoarthritic one. The modified isoform of L-PGDS was detected 
mainly in OA patients, while in non OA individuals L-PGDS in the synovial fluid was 
mainly in the non-modified isoform, except for one N patient with the modified form of 
L-PGDS (1844 N). Due to limited access to the medical data of these patients we 
weren’t able to exclude other inflammatory joints diseases, so we consider these 
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results preliminary and just to demonstrate that chondrocytes release L-PGDS to the 
extracellular space for an unknown function, to be explored. This goes in line with the 
results we found in vitro when chondrocytes were treated with IL-1β or 4BHP in which 
both induced significant inflammation, and consequently the modified isoform of L-
PGDS started to appear in the media.   
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8. Expression of Nrf2: 
In our hypothesis, Nrf2 transcription factor plays an important role in upregulating L-
PGDS gene expression in osteoarthritic chondrocytes. A recent paper showed a 
direct role for Nrf2 in L-PGDS gene expression in bone marrow-derived macrophages 
[108]. Furthermore, a binding site for Nrf2 was identified on the promoter region of L-
PGDS gene. To study Nrf2 response to different inflammatory mediators, we treated 
chondrocytes with IL-1β, IL-17, H2O2 and 4BHP, and checked for the level of 
expression of Nrf2 (total Nrf2). In IL-1β treated chondrocytes, the expression levels of 
Nrf2 were directly increasing with increasing IL-1β doses. Similar results were 
obtained from 4BHP treated chondrocytes (Figure 21). 4BHP as a ROS generator is 
expected to increase the Nrf2 half-life to 200 minutes (see Figure 7 for Nrf2 
pathway), which leads to accumulation of Nrf2 in the cytosol and thus its translocation 
into the nucleus to transcribe ARE genes. We believe that by the same mechanism 
Nrf2 plays a role in L-PGDS gene induction in chondrocytes treated with 4BHP [108, 
126, 127]. The mechanism by which IL-1β contributes to increasing Nrf2 level is not 
well known yet though it may also be through the production of ROS. We plan in 
future work to confirm the involvement of Nrf2 in L-PGDS gene regulation, by using 
Nrf2 agonists like Protandim® and check for the different isoforms of L-PGDS. We 
plan also to check for the loss of L-PGDS induction effect when Nrf2 pathway is 
disrupted by siRNA.    
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Figure 21: Chondrocytes were treated with IL1β in a concentration ranging from 
25pg/ml to 600pg/ml for 48h, or 4BHP in a concentration ranging from 10µM/ml to 
50µM/ml for 24h. Nrf2 levels were detected in 20µg of the cell lysates. (X) Marks an 
empty well in all gels. These experiments were done with different samples and 
different treatments. The results presented here were from IL1β and 4BHP dose 
curves stripped membranes, where they were re-incubated with Nrf2 and further 
developed. We didn’t notice any increase in Nrf2 levels with IL-17 nor H2O2 (results 
not shown).    
 
 
 
 
 
 
 
 
 
 
Figure 21: Nrf2 expression levels in chondrocytes treated with IL1β and 4BHP.
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Chapter 4: Discussion 
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Osteoarthritis:  
Osteoarthritis is a degenerative inflammatory disease where eicosanoids play a key 
role in its pathology. This disease was long thought to be a natural aging process, 
and so inevitable. With deciphering the role of PG’s in OA pathophysiology, research 
made the 1st real step towards a definitive cure for it. Until now most of the 
therapeutics available for OA were managing pain and to some extend joint stiffness 
providing symptomatic treatment only. Hence, these treatments do not slow down or 
reverse joint degeneration. Some experimental techniques are out there to replace 
the damaged cartilage and fill the cartilage gaps using stem cells directed to 
differentiate into new chondrocytes. These techniques are promising but until now 
they do not work perfectly, probably due to the tenacious blood supply of the articular 
cartilage which made the grafts fail.   
OA treatment starts with NSAIDs. Non-selective COX inhibitors were the 1st line used, 
yet they had a lot of side effects from blocking COX-1 enzyme as it plays a vital role 
in the synthesis of constitutive PG’s. COX-2, the inducible form of COX, is the 
enzyme mainly involved in inflammation while COX-1 is mainly involved in normal 
physiological functions. COX-1 through its production of PG’s plays a role in many 
physiological functions in the body among them platelet function and hemostasis, the 
formation of the mucous lining of the stomach and the control of glomerular filtration 
rate and renal function. Hence, the side effects of general NSAIDs necessitated the 
development of a new generation of NSAIDs, the selective COX-2 inhibitors. These 
had fewer side effects, but still they were not 100% COX-2 selective. Moreover, all 
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COX inhibitors suppress PG’s non-selectively as they block the synthesis of 
degenerative and regenerative PGs. This fact raised the concern for a more selective 
approach in treating OA, as patients are probably going to take these medications for 
life.  
From this point of view, we are aiming for an in-depth analysis of which PG plays a 
regenerative role, and how we can up-regulate it or deliver it with minimal side effects. 
Due to the wide range of distribution of systemic drugs including NSAIDs and so the 
wide range of side effects from it, we are focusing on delivering the medication 
locally. Steroids and hyaluronidase injections are widely used nowadays and they 
show equal efficacy in relieving pain and improving functionality [48]. They are more 
efficient and work for a longer duration than oral anti-inflammatory drugs. In this 
context, we are aiming for a product that can be locally injected to antagonize 
inflammation by activating natural anti-inflammatory pathways. Based on what we are 
showing in our results, L-PGDS is present in the synovial fluid under different 
conditions and since it can synthesize “good PGs”, this makes L-PGDS optimum for 
local injection with minimal side effects expected. We showed also from previous 
results that L-PGDS is particularly abundant in chondrocytes of both osteoarthritic 
patients and normal individuals. Moreover, its levels are elevated in chondrocytes 
under different inflammatory conditions. This is assumed to be one of the main 
defense mechanisms of chondrocytes against OA. Based on that, L-PGDS became 
our therapeutic target, especially that the 15d-PGJ2 receptor (PPAR-γ) [124] was 
found to be downregulated in OA, both in vivo and in vitro [85]. We used herein the 
same plan established to treat diabetes type 2, where the problem is decreased 
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insulin production plus downregulation of insulin receptors. The treatment in that case 
focuses on increasing insulin supply from outside as well as increasing the 
expression of insulin receptors. In OA, we can up-regulate PPAR-γ receptors and 
increase its natural ligand (15d-PGJ2) to achieve a higher anti-inflammation effect. 
What we focused on here is increasing 15d-PGJ2 levels through increasing L-PGDS 
expression in articular cartilage. The axis we are working on is detailed in Figure 22, 
where PGH2 the precursor of all PG’s is catalyzed by PGDS to produce PGD2 which 
is then enzymatically dehydrated into 15d-PGJ2. This later triggers PPAR-γ to 
downregulate the expression of inflammatory gene mediators such as COX2, 
MMP1&13, IL-1β, TNF-α as well as iNOS. 
Another interesting function of PGDS is the protection of PGD2 from the non-
enzymatic dehydration into 15d-PGJ2 while transporting it to the site where it is 
supposed to work. This can also explain why chondrocytes release L-PGDS into the 
media and the synovial fluid in cases of inflammation, probably to deliver anti-
inflammatory products or as a paracrine message.  
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Figure 22: PGD2 Anti-inflammatory pathway. 
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The Role of Prostaglandins 
To further understand the roles played by PG’s in OA and to identify potential 
therapeutic targets we went through the literature about this topic. Among 
degenerative PG’s in articular cartilage, PGE2 inhibits proteoglycans formation, one of 
the main components of healthy cartilage. We showed the effect of age-associated 
OA and surgically induced OA, on proteoglycans levels in articular cartilage versus 
normal cartilage in Figure 8 and 9 respectively. PGE2 also increases collagen 
degradation through induction of MMP13 and aggrecanase 5 (ADAMTS-5) which 
degrade cartilage proteins. IL1 is also known to induce MMP13 and ADAMTS-5. 
Furthermore it augments the PGE2 induction of these enzymes and so stimulates 
degradation. These effects are usually blocked by COX-2 selective blockers (like 
celecoxib®), from which comes their therapeutic value as anti-inflammatory in OA. 
The PGE2 effect is mediated through EP4 receptors and these receptors antagonists 
are able to reverse the effect of PGE2, opening the door for new therapeutic targets 
[74]. Oxidative stress has a direct role in inflammation in OA mainly via activation of 
COX-2 and this is reversible by antioxidants like N-acetylcysteine and hyaluronic acid 
[128]. Inhibiting COX-2 leads to suppression of pro-inflammatory PG’s as well as anti-
inflammatory ones. This raises the need for a new strategy in treating OA other than 
the most commonly used one by NSAIDs.  
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The Role of PGDS 
The enzyme Prostaglandin-D synthase is a protein with a wide range of functions that 
are not fully explored yet. However, its enzymatic activity is well understood and it is 
the rate limiting step for PGD2 synthesis from PGH2 and for 15d-PGJ2. PGD2 is a 
well-known anti-inflammatory PG that works through different receptors among which 
DP1 and DP2, these receptors activate cyclic adenosine monophosphate (c-AMP) and 
so increase protein kinase-A (PKA). This leads to a downstream anti-inflammatory 
effect [129]. PPAR-γ is a receptor of 15d-PGJ2 that acts as a transcription factor that 
downregulates important inflammatory mediators and cytokines including COX-2, IL-
1β, TNF-α, iNOS, MMP1, MMP13 [124]. From this comes our focus on regulating the 
Prostaglandin-D synthase enzyme for its potential use as a therapeutic target. This 
aims to induce the intrinsic salvation pathways used by chondrocytes to protect 
themselves against stress. Hence, we studied the role of Prostaglandin-D synthase in 
OA, including its regulation and downstream effects. We focused here on its 
regulation, as its downstream end product 15d-PGJ2 is a well-studied anti-
inflammatory PG. Prostaglandin-D synthase is present in two isoforms, the 
hematopoietic and the lipocalin form. The tissue distribution of these isoforms is 
detailed in Figure 4. Depending on which isoform is present, the function of 
Prostaglandin-D synthase varies; a general overview of the different functions is 
presented in Figure 5. From a previous work in our lab, we showed a specific 
abundance for the lipocalin isoform of Prostaglandin-D synthase (L-PGDS) in 
chondrocytes. Furthermore, we previously showed a particular increase in L-PGDS 
expression compared to H-PGDS in osteoarthritic chondrocytes versus normal [95]. 
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These results directed us to a more focused attention on the regulation of L-PGDS. 
As explained before in the Introduction, L-PGDS is formed of 190 amino acids giving 
it a calculated MW of 21KD and it is post-translationally modified by at least two 
glycosylation sites and many phosphorylation sites [99]. This gives it a wide range of 
MW depending on which modifications take place; each glycosyl group adds 3KD to 
the MW. During our work, we showed that chondrocytes produce L-PGDS in the 
modified form mainly inside the cells and in the non-modified form extracellularly.  
From what we observed in our results, we developed the hypothesis that during 
inflammation chondrocytes release L-PGDS in the non-modified form to suppress 
inflammation. Moreover, since the released isoform of L-PGDS is the non-modified 
form this may suggest a paracrine function for this specific form. While with prolonged 
stress like exposure to 4BHP or IL-1β, chondrocytes release more of the modified 
form of L-PGDS (most likely glycosylated, according to the MW) which may contribute 
to cell death after failure to reduce inflammation. The fact that L-PGDS acts as an 
oxygen free radical scavenger through thiol group in Cys65 at its active site can be 
another explanation for the over production of the glycosylated isoform. This may 
suggest that this form is the most active form as a scavenger. The different functions 
of L-PGDS and the different modifications modulating these functions necessitate an 
accurate identification of which isoform of L-PGDS is doing which function exactly. 
Doing so, we would be able to use the right isoform therapeutically, while avoiding 
potential side effects that may arise from other isoforms. 
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The Role of Nrf2  
Kim et al. in 2013 showed an interesting role for the Nrf2 transcription factor in the 
induction of L-PGDS in murine bone marrow-derived macrophages. Nrf2 is known for 
its protective role against inflammation [130-132]. The mechanism by which it 
suppresses inflammation is variable and still new mechanisms are being discovered. 
Among these mechanisms, Nrf2 plays a role in transcribing ARE genes and Phase 2 
detoxification enzymes. One mechanism presented by Kim et al. shows that Nrf2 
uses also L-PGDS to suppress inflammation in mice. They used murine bone marrow 
derived macrophages to induce L-PGDS by PGD2 (positive feedback mechanism). 
They studied the role of Nrf2 in this process by studying the response in Nrf2 
knockout mice. This effect was lost. Then, they used Nrf2 agonists in one experiment 
and they overexpressed Nrf2 in another experiment to induce L-PGDS. Interestingly 
L-PGDS levels increased with such treatments. Furthermore, they did a sequence 
analysis of the murine L-PGDS gene and identified a binding site for Nrf2 in its 
promoter region [108], showing a role for Nrf2 in L-PGDS gene regulation. Next, they 
observed in mice lung tissues a decreased infiltration of inflammatory mediators and 
neutrophils in response to PGD2-induced Nrf2 mediated L-PGDS induction [108]. In 
chondrocytes, PGD2 has a negative feedback effect on L-PGDS gene expression.  
This was shown in our lab by treating chondrocytes with IL-1β, with or without PGD2, 
which decreased IL-1β induced expression of L-PGDS in PGD2-treated chondrocytes 
[133]. We believe that the same mechanisms shown in murine macrophages and lung 
cells are present in human chondrocytes and that inflammatory mediators induce L-
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PGDS by different mechanisms including the Nrf2 induction pathway. We chose IL-1β 
and IL-17 as inflammatory cytokines because of their well-known role in the induction 
of inflammation. H2O2 and 4BHP were also used because they generate ROS, which 
induce inflammation and contribute to increasing the half-life of Nrf2. This increases 
Nrf2 levels in the cytosol and so stimulates its shift to the nucleus where it expresses 
ARE and L-PGDS genes playing an antioxidant and anti-inflammatory role. The role 
of ROS in Nrf2 pathway activation is detailed in Figure 7. In our results, we could 
detect increasing levels of Nrf2 in chondrocytes treated with IL-1β or 4BHP in a dose-
dependent manner. In IL-17 and H2O2 treated chondrocytes there wasn’t any 
increase in Nrf2 levels (results aren’t shown). IL-1β may have increased the half-life 
of Nrf2 by oxygen free radicals production also, the same mechanism by which 4BHP 
works. Further addressing the role of Nrf2 in L-PGDS induction, future experiments 
should test the use of Nrf2-siRNA to block this pathway and detect to which extent 
this will affect L-PGDS production in response to different inflammatory stimuli.  
The Role of 4BHP 
Treating chondrocytes with 4BHP generates ROS which induce inflammation, and 
when they reach a certain limit they induce cell toxicity and death. What we observed 
during our work was that at higher doses of 4BHP or with prolonged exposure, 
expression levels of L-PGDS decreased in the cell lysate. Concomitantly, the 
modified form of L-PGDS appeared in the cell supernatant increasing with raising 
4BHP dose or duration of treatment. At the same time, cell death, as evaluated by 
detached and floating cells, was noted microscopically with higher concentrations of 
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4BHP as well as with prolonged treatment. 4BHP as a ROS generator has a well-
known role in apoptosis [134]. These results may suggest a role for the modified form 
of L-PGDS in 4BHP-induced cell toxicity and possibly cell death when they were 
treated for 48h. This goes in line with many papers that proposed a role for L-PGDS 
in apoptosis in Alzheimer disease and different cancer cell lines [135-138]. 
Furthermore, a paper suggested that the apoptotic effect was related to the 
glycosylated form of L-PGDS in Alzheimer disease [135]. Another interesting paper 
suggested that the mechanism by which L-PGDS contributes to apoptosis is through 
its transporter function for retinoic acid [137]. The post-translational modification of L-
PGDS has also been linked with its potential apoptotic activity, particularly the 
glycosylation and phosphorylation [139]. The detection of apoptosis markers in 
chondrocytes, such as caspase 3, or cell viability measurements, would give us an 
explanation for the results we had with prolonged 4BHP treatment (Figure 19). This 
hypothesis is currently tested in the laboratory. A further step in understanding those 
modified forms of L-PGDS would be through IP L-PGDS in the cell lysate and in the 
cell supernatant and identifying which modifications are observed upon which 
treatment. In the IP, we would try to detect the glycosylation and phosphorylation 
changes in response to different treatments. This would help us to identify which 
modification is responsible for which function, and eventually find the correct isoform 
that plays an anti-inflammatory role. Hence, we could use the correct isoform as a 
medication avoiding at the same time any potential side effects that may arise from 
other isoforms. 
 
86 
 
 
Our main contribution 
In this study, we showed that chondrocytes produce L-PGDS in response to different 
stimuli and that different forms of L-PGDS are detectable in the cells and secreted by 
these cells. The function of L-PGDS can be affected by which isoform is produced 
and which post-translational modification happens to the protein. Furthermore, its 
location (intracellular and extracellular) in different isoforms suggests different 
functions. Many different studies discussed post-translational modification of L-PGDS 
by glycosylation and/or phosphorylation, as explained in the introduction. Some 
studies also pointed out specific function for different isoforms, we did not directly 
study the function of the different isoforms functions in this study. Instead we used the 
literature to better understand the results we obtained.  
To study arthritis, we induced inflammation in human chondrocytes in vitro. We used 
IL-1β and IL-17 as well-known pro-inflammatory cytokines. Upon treating 
chondrocytes with IL-1β, we observed an increase in L-PGDS expression levels both 
intracellularly and extracellularly in a dose and time-dependent fashion. The isoform 
produced intracellularly (in cell lysate) was the modified one (37KD), while 
extracellularly (in the media), chondrocytes released both modified and non-modified 
isoforms of L-PGS.  
Compared to IL-1β, IL-17 is a weaker pro-inflammatory cytokine; this may partially 
explain why we did not observe an increase in L-PGDS expression levels in dose-
dependent treatment in the cell lysate. While in the time course treatment, a bell-
shaped curve rise in L-PGDS levels was detected in the cell lysate. In all cell lysates, 
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chondrocytes produced the modified form of L-PGDS (37KD). In contrast, we 
detected a bell-shaped curve rise of the levels of the non-modified form (25KD) of L-
PGDS in a dose and time-dependent manner in the cell media, hence representing 
the secreted form of L-PGDS.  
We also used 4BHP and H2O2 as ROS generators to induce inflammation and also 
increase Nrf2 half-life allowing it to translocate into the nucleus and transcript ARE 
and L-PGDS. We hypothesized this based on different studies showing a role for Nrf2 
in L-PGDS induction, as detailed in the Introduction.  
Treating chondrocytes with 4BHP for 24h showed an increase in expression levels of 
L-PGDS in a dose-dependent manner. This was observed both intracellularly and 
extracellularly. In addition, L-PGDS was detected in the cell lysate in the modified 
isoform and in the media in the non-modified isoform. When we tried treating 
chondrocytes with 4BHP for longer periods (>24h) we observed signs of cell toxicity 
and death. A big percentage of cells were detached and floating in the media, 
suggesting cell death or at least toxicity. However we did not perform quantification of 
cell death or toxicity nor apoptosis markers here, we only used this observation to 
adjust the 4BHP dose and time of exposure in further experiments. Interestingly, 
during the prolonged treatment (48h), L-PGDS levels, in its modified form, were 
decreasing in the cell lysate with increasing doses of 4BHP. Though, L-PGDS levels 
continued to rise in the media albeit in the modified isoform, for the 1st time for all 
4BHP experiments. We observed also in the media decreasing levels of the non-
modified isoform of L-PGDS with increasing 4BHP doses. This would suggest that 
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there is a shift from the non-modified isoform to the modified isoform with increasing 
4BHP dose (at 48h). These results are summarized in Figure 19.  
The observed detached and floating chondrocytes suggests a toxic effect for 4BHP at 
48h of exposure and a possible relation between this toxicity and the modified form of 
L-PGDS. This observation drove us to adjust the dose and time of exposure of 
chondrocytes to 4BHP to 24h only. This also limited our capacity for testing a time 
course effect of 4BHP on chondrocytes as we had inconsistent results, hence they 
were not included in this study.  
H2O2 is a weaker ROS generator due to its instability at 37oC. Treating chondrocytes 
with increasing H2O2 doses for 24h did not show an increase in L-PGDS expression 
levels in the cell lysate. In the media however, we observed increasing levels of the 
non-modified isoform of L-PGDS in a bell-shaped curve with increasing H2O2 dose. 
In the time course experiments, a small increase in L-PGDS levels in cell lysates was 
observed at 6 hours; this level was maintained with longer exposure. L-PGDS was 
detected in the cell lysates in the modified isoform also. This suggests a saturated 
induction of L-PGDS by H2O2. In the supernatants, L-PGDS could not be detected 
mainly due to the weak effect of H2O2 on L-PGDS induction and due to the instability 
of H2O2 overtime. These findings, along with the bell-shaped curves in previous 
results may suggest that L-PGDS is not stable and that there is a degradation 
mechanism to clear it when the inflammation process is stopped (for example when 
H2O2 is degraded).  
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The appearance of the modified isoform of L-PGDS in the cell lysates and in the 
media of 4BHP and IL-1β treated chondrocytes can be explained by L-PGDS function 
as an oxygen free radical scavenger as detailed in the Introduction. This L-PGDS 
function is achieved mainly through the thiol group at Cys65. Why chondrocytes 
release L-PGDS either in the non-modified isoform or the modified isoform is not fully 
understood yet. This may be part of a paracrine system to the surrounding cells to 
induce anti-inflammatory effect in the adjacent cells as well as in chondrocytes.  
The different functions of L-PGDS and the different modifications modulating these 
functions necessitate accurate identification of which isoform of L-PGDS is the one 
working as anti-inflammatory, so we can use the right isoform therapeutically to avoid 
possible side effects from other isoforms. 
In 4BHP and IL-1β dose curves experiments that showed increased expression of L-
PGDS in the cell lysates, the nitrocellulose membranes were stripped and re-
incubated, we tested the presence of Nrf2. Interestingly, both treatments (4BHP and 
IL-1β) showed increased Nrf2 expression levels as well. The mechanism by which 
4BHP increases Nrf2 by generating ROS was explained in details in the introduction, 
but the IL-1β involvement in Nrf2 expression levels is not fully understood yet. This 
could be due to ROS production by IL-1β in chondrocytes. The increase in Nrf2 and 
L-PGDS levels in chondrocytes treated with IL-1β and 4BHP goes in line with the 
studies that discussed a direct role for Nrf2 in L-PGDS induction, as detailed in the 
Introduction. This role is important because we can use a Nrf2 agonist therapeutically 
to induce L-PGDS in articular cartilage by local injection, to suppress inflammation.  
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Aiming to study the release of L-PGDS by chondrocytes in vivo, we tried detecting L-
PGDS in different synovial fluid samples. Interestingly, L-PGDS was found in many 
different synovial fluid samples from OA patients and normal individuals both in the 
modified isoform and the non-modified isoform. Due to limited access to these 
individuals’ medical records we couldn’t exclude other joint diseases in the non OA 
patients, hence we have limited possibilities to explain the presence of both isoforms 
in the “normal” samples. This needs further studying to identify in which conditions L-
PGDS is released into the synovial fluid and in which isoform. The results from the 
synovial fluids confirmed only our in vitro findings that chondrocytes release L-PGDS.  
Aiming to study the production of L-PGDS inside the chondrocytes in vivo, we 
detected L-PGDS expression levels by immunohistochemistry in OA mice models 
versus normal mice. OA was induced via two different routes, either surgically by 
DMM or naturally by aging. Sham surgery mice models were used as a control for 
DMM surgery, and young mice were used as a control for the age-induced OA 
models. There was a 3-5 fold increase in L-PGDS expression levels in OA models, 
either surgically-induced or age-induced. All the OA models were first confirmed 
histologically, by staining some slides with safranin-O and fast green to identify the 
characteristic pathological lesions of OA histologically. Hence, these data confirmed 
our in vitro studies of the potential role of L-PGDS in OA pathology.  
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Limitations: 
One of the important limitations we had during this study was the toxic effect of 4BHP 
on human chondrocytes with prolonged exposure. Therefore, we couldn’t determine 
L-PGDS expression patterns in 4BHP time course treatments.  Alternatively we may 
try using lower doses of 4BHP or higher doses of H2O2 with a more frequent 
application (6h) to generate enough ROS without inducing cell toxicity. H2O2 instability 
also was a limitation. In vivo studies weren’t enough, and so we may try silencing L-
PGDS gene by siRNA or knockout model and observe the inflammatory effect of IL-
1β on the induction of COX-2, iNOS or MMP1, 13 for example. Comparing those 
results in knockout mice versus normal mice can reflect L-PGDS anti-inflammatory 
effect if COX-2 and iNOS levels are higher in the knockout. We may also use siRNA 
or knockout mice for Nrf2 to confirm its role in L-PGDS induction in response to 
different stimuli. We can also use a Nrf2 vector to overexpress the gene in 
chondrocytes and observe its effect on L-PGDS levels. 
We couldn’t collect synovial fluid samples from mice to detect L-PGDS under different 
conditions, so we may collect dogs’ samples or humans’ synovial fluid samples from 
different OA patients as well as normal volunteers to detect L-PGDS levels and its 
different isoforms.  
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Future studies: 
This study opens the door for many other questions to answer. In future projects, we 
should try to identify which isoform of L-PGDS is produced in the media, synovial fluid 
and inside the chondrocytes themselves in response to different other inflammatory 
stimuli. This can be done by immunoprecipitation techniques where we can pull-down 
L-PGDS and check for glycosylation or pull-down glycosylated proteins and check for 
L-PGDS among them. We can also use glycosylation inhibitors and observe the loss 
of protein bands or change in L-PGDS band location in WB. The same techniques 
can be used for detection of the phosphorylated form of L-PGDS.  
Another interesting question would be to assess the effect of Nrf2 agonists on L-
PGDS expression levels and different isoforms. This can be tested by using Nrf2 
agonist or deliver Nrf2 by a vector inside the chondrocytes to overexpress it, and then 
we could observe the changes of L-PGDS levels and isoforms. 
Further studying L-PGDS anti-inflammatory effect, we could treat chondrocytes with 
L-PGDS and then measure their response to inflammatory mediators (for example IL-
1β), by detecting other inflammatory gene expression levels (like COX-2, iNOS, 
MMP1 and 13). Another way to do it would be by silencing L-PGDS gene with siRNA 
and see if this will lead to a more inflammatory response in chondrocytes when 
treated with IL-1β for example.  
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Chapter 5: Conclusion 
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From our results, we conclude that L-PGDS is produced by human chondrocytes in 
vitro in response to different inflammatory stimuli. This happens in response to 
inflammatory cytokines and ROS generators, aiming to ameliorate inflammation. The 
same process happens in vivo, for example in mice articular cartilage in response to 
mechanical stimuli generating OA. L-PGDS induction is dose and time dependently 
expressed in response to the inflammatory stimuli. Chondrocytes release L-PGDS 
into the media in vitro and the synovial fluid in vivo in response to different 
inflammatory stimuli. This is probably a paracrine function to suppress inflammation 
even in the surrounding tissues. The fact that L-PGDS is present in the synovial fluid 
is interesting when we think about using it locally as a medication, avoiding possible 
systemic side effects. There are different isoforms of L-PGDS depending on which 
post-translational modification happened to the protein. This modulates its function in 
response to different stimuli and in different locations. Consistent with what we found 
in the literature review, our results suggest that some isoforms of L-PGDS (probably 
the glycosylated isoform) may play a role in cell toxicity in human chondrocytes. The 
fact that there are different isoforms of L-PGDS, and that some may contribute to cell 
death, raises the concern for identifying which isoform is enzymatically active as anti-
inflammatory and which isoform is contributing to cell death so we can work on the 
right isoform as a therapeutic target. Nrf2 is induced in human chondrocytes by 
different inflammatory mediators, either cytokines or ROS generators. Nrf2 is most 
probably one of the pathways by which L-PGDS gene is induced in response to 
inflammation. This opens the door for another potential therapeutic target using Nrf2 
direct ligands to induce L-PGDS.  
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